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Abstract
Notch signaling plays a critical role in regulating vascular morphogenesis. In vascular
interventions, the endothelial cells (ECs) are often damaged, and EC-SMC contact is
compromised. The objective of this study was to investigate if immobilized Jagged1 can act as an
EC-surrogate material to direct and control vascular smooth muscle cell (VSMC) behavior via
Notch signaling. It was shown that immobilized Jagged1 induced vascular differentiation of iPSCderived mesenchymal stem cells and mouse embryonic multipotent cells. Immobilized Jagged1
was insufficient to induce mature contractile markers in coronary artery SMCs; therefore, serum
starvation and TGFβ1 treatment were investigated. Although Notch signaling is mechanosensitive
in nature, it was also determined that a pulling force was not needed for Notch3 activation. Overall,
it is concluded that immobilized Jagged1 is an essential regulator in SMC phenotype and SMC
differentiation. These findings may have clinical relevance for modulating VSMC phenotype in
cardiovascular disease states and in tissue engineering.

Keywords: Notch3 Signaling, Jagged1, Vascular Smooth Muscle Cells, Phenotype Regulation,
Mechanotransduction
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Summary for Lay Audience
To treat atherosclerotic vessels, stent deployment is a common intervention, but unintentional
damage to the endothelial cell (EC) layer can cause smooth muscle cell (SMC) dysregulation. The
Notch signaling pathway plays a critical role in regulating SMC phenotype switching through
Jagged1-Notch3 signaling between EC and SMCs. Little is known on biomaterial approaches to
direct Notch signaling and how ligand presentation strategies affect SMC response. Therefore, this
study proposed bead-bound Jagged1 cell surrogates as a model in regulating the contractile VSMC
phenotype. This study aimed to determine how immobilization strategies, crosstalk and cell source
affected signaling response. Jagged1 was attached to magnetic nanoparticles and targeted binding
to the Notch3 receptor on human coronary artery SMCs, iPSC-MSC, or pre-differentiated 10T1/2
cells. The use of bead-bound Jagged1 suggests high potential in modulating the development and
maturation of the vasculature. Findings may have clinical importance and therapeutic potential for
modulating vascular SMC phenotype during various cardiovascular disease states and in tissue
engineering, with the possible application for bioactive stent materials.
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Chapter 1. Introduction
This chapter provides an overall introduction and objectives of the thesis work.

1.1. Overview
The incidence of cardiovascular diseases (CVD) is one of the major causes of death
worldwide and is a leading concern to medical professionals worldwide. Over 2 million Canadians
live with diagnosed ischemic heart disease, and over 150 000 Canadians are newly diagnosed a
year, indicating the high prevalence of heart disease in Canada1. Atherosclerosis is one of the
leading causes of coronary artery disease (CAD) pathogenesis and is a major underlying cause of
CVD. Atherosclerosis is the build-up of fatty plaque-like material in the intima of coronary, carotid
and peripheral arteries causing narrowing and reduced blood flow2. While angioplasty is a
common intervention for mild blockages, for severe CAD (e.g., multiple blockages of coronaries
bypass, grafting is needed (which include autologous vessels or synthetic grafts).
Coronary artery bypass grafts are very invasive and have complications including
thrombosis and neointimal formation, leading to graft failure, donor site morbidly, and immune
rejection. The emergence of tissue-engineered blood vessels to overcome these drawbacks aim to
produce functional substitutes and are being extensively investigated3–5. An alternative is to take
a less invasive surgical approach by deploying stents through balloon angioplasty surgery to
restore blood flow in the vessel. Coronary artery stents, including metal stents, drug-eluting stents
(DES), biodegradable stents, and bioactive stents (BAS) have been designed 6–8. These designs
have shown some success; however, restenosis is still a major issue that has been attributed to
vascular arterial damage of the inner endothelial cell layer, suspected to occur during stent
deployment9,10.
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There is a direct dependence that the smooth muscle cell (SMC) phenotype has on the
presence of endothelial cells (ECs)11–15, and there have been mechanisms proposed that govern
their cellular interactions. Notch signaling has been suggested as a major regulator in the
vasculature, and the Notch driven relationship helps to control SMC phenotype regulation13,16.
Many researchers have investigated factors that control SMCs, including; matrix components,
growth factors, scaffold geometry, mechanical stimulation, as well as coculture interactions14,17.
Although it is hard to fully recapitulate the native EC-SMC interactions, there is a push towards
trying to imitate native function and trigger a proper cellular response. Many bioactive/biomimetic
stents have been proposed to mimic natural cell-cell communication. The Notch ligand Jagged1
could be a potential bioactive protein to maintain SMC contractile function and can be
incorporated into stents or other biomaterial design. Understanding the mechanism from a
biological perspective and translating this knowledge into tissue engineering can allow the design
of more accurate and physiologically relevant stents or biomaterial substitutes. These can be
incorporated to improve the signaling capability of Notch signaling. Therefore, a deeper
understanding of biomaterial-directed Jagged1 Notch signaling behavior in the context of
controlling SMCs in the vasculature will enable functional the design of functional engineered
substitutes for the treatment of vascular diseases.

1.2. Thesis outline
This thesis has five chapters that outline and detail the work carried out. Chapter 2 introduces
the role of Notch signaling in developmental biology, the role of Notch signaling in the
vasculature, as well as current proposed strategies to modulate and control Notch signaling in a
tissue engineering context. Furthermore, it illustrates the motivation for this study; to develop a
functional stent material to improve stent restenosis and outlines the thesis objectives. The
2

materials and experimental methodologies used are described in Chapter 3 followed by a
discussion on significant research findings of this work in Chapter 4. Finally, Chapter 5
summarizes the research and provides the significance and future directions.
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Chapter 2. Literature Review *
This chapter discusses the relevant background information and current progress in achieving
Notch signaling biomaterials for vascular tissue engineering and regenerative medicine
approaches.

*A portion of this chapter (Section 2.4 and following) was expanded and published in a recent
review paper:
Kathleen Zohorsky and Kibret Mequanint. Designing biomaterials to modulate Notch
signaling in tissue engineering and regenerative medicine. Tissue Eng. (B). 2020
doi.org/10.1089/ten.TEB.2020.0182

2.1. Structure and function of blood vessels
Blood vessels are a part of a complex network that makes up the vasculature and allow blood,
oxygen, and nutrient transfer throughout the body. Oxygen-rich blood leaves the heart through the
aorta, which branches into arteries, smaller arteries, arterioles, and finally capillaries. Capillaries
are permeable to oxygen (moves from the capillary to the cells) and carbon dioxide (moves from
the cells to the capillaries). The oxygen-depleted blood is then transported back through the
capillaries, into small venules, veins, and finally enters the vena cava into the upper right atrium
of the heart. Apart from the small arterioles and capillaries, the functional blood vessels are
composed of three distinct concentric layers that vary in function depending on the location and
purpose of the vessel. The structure and development of arteries and veins both differ due to the
various functions that they play within the body. Veins have a functionally thinner tunica intima
than that of arteries because they do not have a primary contractile function. Arteries have a much
thicker tunica intima. The structure of a muscular vascular wall (eg. Coronary artery) and its
cellular components are shown in Figure 2-1.

5

Figure 2-1 Structure of a muscular vascular wall (e.g., coronary artery)
A) Artery cross-section B) Structure of the arterial wall and the cellular makeup. Depiction of the
three vascular layers, tunica intima, tunica media, and tunica externa which come together to form
the vascular wall (Reproduced from ref 1 with permission Copyright © 2015 Zhao, Vanhoutte, and
Leung, Production and hosting by Elsevier B.V).

2.2. Components of the vascular wall
The vascular wall is made up of three layers; tunica intima, tunica media, and the tunica
externa. The innermost layer of the artery which lines the lumen of the vessel is the tunica intima
(also referred to as the endothelium) which consists of a monolayer of endothelial cells (ECs)
attached to a basement membrane of extracellular matrix (ECM) proteins. The functional relevance
of the endothelium is to protect and respond to external stimuli, which functions as a barrier
between the blood flowing in the lumen and the surrounding tissues. The endothelium produces
several vasodilator and vasoconstrictor substances that regulate not only vasomotor tone but also
the recruitment and activity of inflammatory cells and control its tendency towards thrombosis1–3.
By communicating with smooth muscle cells (SMCs) in the vascular wall, ECs can decrease or
increase arterial diameter by altering its contraction and relaxation behavior4.
Adjacent but in contact with the intima is the tunica media, which contains multiple layers
of densely packed SMCs with fenestrated elastic lamellae interspersed between them. These SMCs
6

are capable of switching between a contractile phenotype found in physiological conditions and a
synthetic phenotype, which is characteristic of developmental (proliferative), or pathological
conditions5. There are many characteristic and functional differences between the two phenotype
conditions. Cells in a contractile phenotype have a spindle-shaped morphology, a centrally located
nucleus, and proliferate at a very low rate but have robust contractile protein. A morphology
transition to a more synthetic phenotype mimicking that of fibroblasts occurs upon stimulation by
various conditions such as inflammation, high levels of ECM production, mechanical forces,
soluble factors, and signaling cues from ECs. The SMC phenotype continuum and modulation is
presented in Figure 2-2.

Modulated by:
• Inflammation
• ECM components
• Mechanical forces
• Soluble factors
• Endothelial cells

Synthetic

VSMC Phenotype Continuum

Contractile

Figure 2-2. Phenotype regulation continuum of VSMCs.
Phenotype switching between a synthetic and a contractile phenotype is modulated by various
biochemical and mechanical cues, including; inflammation, ECM components, mechanical forces,
soluble factors, and endothelial juxtacrine signals. (confocal images legend; green: F-actin,
red:Acta2; yellow: Cnn1. Images taken by Shigang Lin and Stephanie Grenier).
The key components of the contractile apparatus in VSMCs are smooth muscle myosin
heavy chain (SMC-MYH) isoforms and SM a-actin (Acta2), along with the contractile filament
smoothelin B which is expressed in mature VSMCs5,6. Other characterized markers of VSMC’s
7

include transgelin and the calcium-binding protein and inhibitor of SM-MYH intrinsic ATPase
activity, calponin6. Regulation of the actin cytoskeleton and contractile machinery of VSMCs are
important for vascular homeostasis. Within their contractile phenotype, SMCs relax and contract
in a cascade manner to increase or decrease the vessel diameter, thus changing blood flow rate
through the lumen. Contractions can be modulated by mechanical (intraluminal pressure, lumen
stretch/compression), electrical, or pharmacological activation7.
The outermost layer of the artery is the tunica externa and is largely composed of
fibroblasts and collagenous ECM proteins. This layer primarily functions to protect and anchor the
artery to the surrounding tissue. In addition to these three aforementioned layers, the artery has
internal and external elastic membranes. These elastic tissues aid the vessel wall to maintain
structure and resilience and impart arterial elasticity under pulsatile flow. The mechanical integrity
of the vessel is important to support external forces and maintain its intrinsic contractility. The
mechanical properties of the blood vessel arise from a network of ECM components and their
interactions with the cells. The matrix is composed of a network of fibrous proteins, mostly
collagen and elastin, and a basement membrane composed of the elastic lamina, collagen IV, and
fibronectin (FN) embedded in a hydrogel of proteoglycans and several glycoproteins8. These layers
provide mechanical support, anchorage of the cells, guidance, the transmission of mechanical
forces, and restricts the vessel from mechanical deformation8.
Blood vessels experience various forms of mechanical forces; stretch (through muscle
distention), cyclic strain (from pulsatile blood flow), compression (due to differential blood
pressure), surface force (from systolic blood flow), and shear stress (blood drag force)4,9. These
various forces control and regulate the function and homeostasis of the blood vessel. The
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endothelial cells which line the lumen of the vessel can sense pressure and blood flow and they
are capable of transducing changes in mechanical forces into changes of the SMC tone3.

2.2.1.

Structure and function of the coronary arteries
The coronary arteries originate at the root of the aorta and split into two branches that

vascularize the myocardium. The left coronary artery supplies blood to the left atrium and left
ventricle of the heart, while the right coronary artery supplies blood to the right atrium and right
ventricle of the heart. Coronary arteries are very muscular by nature, having the bulk of the arterial
wall made up of the media layer to provide this muscular tone. The elastic laminae surrounding
the tunica media allow the artery to recoil and prevent vascular dilation that would result from the
creep of collagen under high blood pressures10. Properties of the coronary artery including
diameter, stress, wall thickness, transport blood pressure, burst pressure, and longitudinal strains
can be summarized in Table 2-1.
Table 2-1 Properties of the coronary artery
Property

Reported Range 8

Internal diameter

~ 3- 4 mm

Stresses

0.75 -2.25 Pa

Wall thickness

~ 1 mm

Transport blood pressure

80-120 mmHg

Burst pressure

~ 2000 mmHg

Longitudinal strains

10-15 %
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2.3. Diseases of the coronary artery
Since coronary arteries deliver blood to the heart muscle, all coronary artery
disorders/diseases can have serious health implications. Cardiovascular disease (CVD) is defined
as any physiological condition that causes the impaired function of the heart or blood vessels
within the circulatory system. Myocardial infarction (MI) is often the consequence of prolonged
CVD and results due to the blockage of blood supply to the myocardium caused by ischemia (lack
of oxygen and nutrients) in one or more coronary arteries11. Coronary artery disease (CAD) is a
type of CVD and is one of the leading causes of morbidity and mortality in the world12. The
development of atherosclerotic lesions in the coronary artery is one of the central components of
CAD. Atherosclerosis is characterized by the buildup of plaque in the inner lining of an artery
causing it to narrow or become blocked and is the most common cause of heart disease and is a
leading cause of CVD and MI13. Major risk factors for atherosclerosis are aging, diet, diabetes,
smoking, lifestyle, and genetics. The three stages of development in atherosclerotic lesions are
depicted in Figure 2-3. A depiction of the normal muscular vascular in which the vessel is in
homeostasis (Fig. 2-3 A) can be compared and contrasted to the development and progression of
atherosclerosis ( Fig. 2-3 B-D).
Atherosclerosis can be caused by many biological mechanisms, including endothelial
dysfunction, which creates increased permeability of the endothelial barrier and allows for the
abnormal accumulation of plasma-derived lipids and oxidation products within the arterial wall14.
The retention of low-density lipoproteins’ creates a vascular response inducing leukocyte
adhesion, the recruitment of inflammatory cells to the injury site, and recruitment of monocytes
from the peripheral blood, which become activated macrophages13,15.
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Figure 2-3 Stages of development of atherosclerotic lesions
A) The 3 normal artery layers (intima, media, and adventitia), and overall vessel homeostasis. B)
Stage1-Adhesion of blood leukocytes to the activated endothelial monolayer, migration of
leukocytes into the intima, maturation of monocytes into macrophages and uptake of lipids
creating foam cells. C) Stage 2- lesion progression involving migration of SMCs from the media
into the intima, proliferation of SMCs and heightened synthesis of extracellular matrix
macromolecules. Cell death and apoptosis of both macrophages and SMCs are often seen in
advancing plaques, and the extracellular lipids accumulate in the central region of the plaque,
creating the lip or necrotic core. D) Stage 3 – Thrombosis and ultimate complication, including
physical disruption of the plaque. Depicted here is the rupture of the plaques fibrous cap and
thrombus formation. (Reproduced with permission from ref 15. © Copyright 2011 Macmillan
Publishers Limited.)
The altered cell state and lost cell communication is one aspect that contributes to the development
of fatty plaque deposits14. The dysregulation of the artery wall also leads to SMC phenotype switch
and subsequent migration of the SMCs from the medial layer into the intima where they synthesize
matrix molecules that mature the plaque further. Atheroma formation includes components like
foam cells, lipid-laden macrophages, and SMCs from the tunica media. The SMCs also produce
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ECM molecules, including interstitial collagen and elastin which form a fibrous cap that covers
the plaque14. This multistep response by the body ultimately aims to protect and strengthen the
weakened vessel wall, however inadvertently, the artery lumen narrows and causes serious health
complications. Recently an in-depth analysis of atherosclerosis biology and the progress and
challenges of biological translation and treatment has been reviewed 15. This is important to gauge
the understanding of various treatment options for cardiovascular diseases and atherosclerosis.

2.3.1.

Atherosclerosis treatment options

Both surgical and pharmacological methods are used for atherosclerosis treatment. The most
common surgical techniques used to treat cardiovascular diseases are i) coronary artery bypass
surgery and ii) balloon angioplasty and stenting. Coronary artery bypass grafting is an invasive
surgical method. These grafts are primarily sourced from autologous tissues16,17, however other
allograft and xenograft tissues are available (but these are associated with a high risk of immune
rejection and potential disease transmission). Patients with unavailable autologous tissues can also
receive synthetic grafts such as Teflon® and Dacron®. Research into developing synthetic tissueengineered vascular grafts is still ongoing to improve the design and minimize complications.
Coronary artery angioplasty is another common, less invasive surgical technique used to
restore blood flow in an affected artery. Stents are inserted through a thin tube (catheter) into the
narrowed part of an artery. A wire with a deflated balloon is passed through the catheter and the
balloon is then inflated, compressing the fatty deposits against the artery walls. Stents are often
left in the artery to keep the artery open, and some stents slowly release medication to help keep
the arteries open.

Stent technologies can be grouped into six categories (Appendix A1:

Advantages and disadvantages of current stent technology): a) bare b) coated metallic stents,
c) drug-eluting stents (DES) e) biodegradable stents and f) bioactive stents (BAS). The
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development of stents was driven because of acute vessel closure18; however, one major clinical
concern with all stent designs is in-stent restenosis19,20. Stent design has progressed, but there is
no perfect solution to stop this complication.

2.3.2.

Stent-induced the coronary artery injury
In-stent restenosis, defined as the gradual re-narrowing of a stented coronary artery lesion

due to arterial damage with subsequent neointimal tissue proliferation, is a major clinical problem.
Restenosis has shown to occur following angioplasty in 20-40% of coronary lesions within a 6month postoperative timeframe18. Restenosis can be attributed to many types of vascular injury,
including EC dysfunction as well as ECM disruption. The deployment of the stent can cause
mechanical damage (splitting atheromatous plaque and stretching of the vessel wall) to the arterial
wall or scraping of the endothelial layer and inadvertently damaging endothelial cells21,22. Injury
mechanisms of the vasculature have been examined in vivo, in vitro, and have been
computationally modelled23–26. Overall, it has been proven that the integrity of the EC monolayer
is important in maintaining vascular homeostasis3,27,28. The EC-SMC communication loss can
cause VSMCs to undergo a phenotype switch from a contractile to a more proliferative synthetic
type. It is this synthetic phenotype that have a high proliferative capability and are observed to
migrate into the lumen and cause restenosis of the artery. Additional to signals from ECs, the
disruption to the surrounding ECM has also been shown to affect changes in SMC phenotype and
activation; matrix-degrading metalloproteinases degrade the collagen in the ECM, which are
known to regulate VSMC behavior29.
Although stent technology has made considerable progress in terms of improving patient
outcomes, no single technology on the market has been completely successful. Thus, using
biological mechanisms occurring naturally in the arterial wall allows us to create innovative
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engineered solutions. If biological factors are incorporated into stents or biomaterials, it will
enhance treatment outcomes for vascular disorder and disease progression, which could provide
useful insights when exploring novel bioactive stents and bioactive materials.

2.4. Cell signaling pathways
Studying native cell signaling pathways and their influence on SMC response becomes
increasingly important to provide insight on better designs for tissue-engineered solutions. Within
the vasculature, cells continuously send and receive signals that are essential for development,
homeostasis, and repair of various tissues and organs. They are able to adjust to their
microenvironment and communicate with each other through a complex network of signaling
pathways. In general, in the body, cells can receive information through 4 types of signaling
depending on the tissue type and the distance the signal has to travel; autocrine, endocrine,
paracrine, and juxtacrine (Fig. 2-4 A-D). In tissue engineering, cells signal predominantly by
paracrine or juxtacrine signaling30. The difference between paracrine and juxtacrine signaling is
the mode of ligand presentation31,32. In paracrine signaling, the ligand is secreted by one type of
cell and is released into the neighboring target cells as a diffusible soluble factor. In juxtacrine
signaling, the ligand is anchored on the signal-sending cell surface to bind the receptor on another
cell, thus requiring cell-cell contact for proper function.
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Figure 2-4 Cell signaling types and an overview of the canonical Notch signaling cascade.
A) Paracrine signaling is short-range signaling using soluble factors. B) Autocrine signaling
signals itself using various excreted factors. C) Paracrine signaling is a long-range signaling type
delivered through the bloodstream. D) Juxtacrine signaling is a short-range signaling where cellcell contact is needed through ligand-receptor interactions or gap junctions. E) The Notch
signaling pathway a common juxtracrine signing pathway and plays an important role in the
vasculature. Published as Kathleen Zohorsky and Kibret Mequanint. Tissue Eng. Part B, ©
Copyright 2020, Mary Ann Liebert, Inc.
Common intracellular signaling mechanisms in the body include the Wnt signaling, the sonic
hedgehog (Shh) signaling, the bone morphogenetic protein/transforming growth factor b
(BMP/TGFb) signaling, and Notch signaling, to name a few. Notch signaling is an important
heterotypic and homotypic juxtacrine cell-to-cell signaling pathway that is active in numerous cell
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fate decisions, including development, tissue maintenance, homeostasis, as well as disease
progression33–35. Its various tissue-specific roles allow for Notch signaling to be a promising target
for cellular control. Most importantly, Notch signaling plays a vital role in the vascular. Notch
signaling in combination with other pathways also allows for signaling crosstalk which can be
therapeutically useful36–38. In view of this, Notch signaling, and Notch modulation will be
discussed further.

2.5. The Notch signaling pathway
Notch signaling is simple in design with few core signaling components, as seen in Figure
2-5, however it is complex from a regulation perspective as it affects numerous distinct cell fate
decisions and is important in the development of many tissues39. Notch signaling is a critical
heterotypic juxtacrine cell-to-cell signaling pathway that is active in numerous cell fate decisions,
including development, tissue maintenance, homeostasis, as well as disease progression33–35. Its
various tissue-specific roles allow for Notch signaling to be a promising target for cellular control.
Notch signaling is an evolutionarily conserved mechanism regulated by interactions with
transmembrane proteins of the Jagged or Delta-like (Dll) family of ligands. Mammalian tissues
express various combinations of four Notch receptors (Notch1, Notch2, Notch3, and Notch4) and
five Notch ligands (Jagged1, Jagged2, Dll1, Dll3, Dll4) and signaling is activated through three
sequential cleavages, named as S1, S2, and S3 cleavages. In S1, Notch is cleaved into a
heterodimer by Furin-like convertase, which undergoes O-fucosylation by O-Fucosyltransferase
and glycosylated by Fringe in the Golgi before the receptor is transported to the cell membrane.
This processing step controls the abundance of Notch receptors at the cell surface. The binding
interaction between a specific Notch receptor with a corresponding ligand initiates the regulated
intramembrane proteolysis, resulting in a conformational change of the Notch extracellular domain
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(NECD) of the receptor. This conformational change exposes an S2 cleavage site for the
metalloprotease ADAM17/TACE to initiate. In the absence of ligand binding, the Notch receptor
is maintained in an autoinhibited and protease-resistant state40. There is extensive evidence
implicating NECD endocytosis in Notch signaling force generation (this is expanded in
Section 2.7.2); however, the mechanism and purpose is still highly debated 40–44.

Figure 2-5 The Notch signaling cascade.
Detailed description of this pathway provided in the text. Published as: Kathleen Zohorsky and
Kibret Mequanint. Tissue Eng. Part B. 2020 , © Copyright 2020, Mary Ann Liebert, Inc.
Full activation of Notch is achieved upon S3 cleavage of the Notch extracellular truncation
(NEXT) by presenilin, the proteolytic subunit of the $-secretase complex, which cleaves the Notch
intracellular domain (NICD). Once released from the plasma membrane, the NICD translocates
into the nucleus, where it binds to the transcriptional repressor RBPJ (recombination signal17

binding protein for immunoglobulin κ J region, also known as CSL and CBF1). Finally, the NICD
activator complex promotes transcription of downstream gene targets, including Hairy Enhancer
of Split (HES) and HES related with YRPW motive (HEY), as well as various downstream
functional genes and proteins45,46
Unlike other signaling pathways that are enzymatically amplified, Notch signaling instead
depends on stoichiometric receptor-ligand interactions to activate it, and any imbalance may
inhibit the process39,47. From what seems like a simple mechanism when compared to other
signaling pathways, the regulation and modulation of Notch signaling is very complex and tissue
specific. Distribution of the Notch signaling components in different tissues vary considerably,
thus interpreting these context-specific effects of Notch will ultimately require that the wiring of
the regulatory networks in which it operates is understood34. The importance of specific ligandreceptor pairings to develop new therapeutic targets must be investigated. Understanding the role
of Notch in tissue specification during development and disease state is beneficial to translate these
mechanisms into tissue engineering48. Although the principle of tissue engineering can be applied
to many tissues, the focus of this research is on vascular tissues. In view of this, important
biological processes in the vasculature driven by Notch signaling will be identified.

2.5.1.

Notch modulation in the vasculature
Vasculogenesis is the differentiation of precursor cells (angioblasts) into ECs and the de

novo formation of a primitive vascular network, whereas angiogenesis refers to the growth of new
capillaries from pre-existing blood vessels. Notch signaling is critical in both vasculogenesis
during development and in angiogenesis49,50. It protects the endothelium51, controls VSMC
phenotype52–55, promotes neoangiogenesis56–58, tip-stalk cell patterning59, and regulates
arteriovenous specification60,61. The various roles of Notch signaling in the vasculature, including
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its influence on ECs and SMCs have been reviewed previously35,62. In this section, important
Notch receptor-ligand pairings in the vasculature are highlighted. VSMCs dominantly express
Notch1, Notch2, and Notch3 receptors, while ECs express Notch ligands Jagged1, Jagged2, Dll4,
and to some extent Dll1 in the remodeling vasculature6,63. The context in which these ligands and
receptors occur is essential; however, the anatomical location within the vascular bed and the
associated physiological forces (flow and stress) are likely to impact the context-dependent Notch
activation56.
The growth of the vascular system involves tip cell selection, sprout formation, tip cell
migration, stalk cell proliferation, and ultimately vascular stabilization64 which are collectively
influenced by Notch signaling. Vascular sprouting (Fig. 2-6 A) is guided by the migration of tip
cells in response to a matrix-bound vascular endothelial growth factor (VEGF) gradient59,65, with
Dll4 acting downstream as a negative regulator66,67. Tip-stalk cell fate plays a significant role in
angiogenesis since tip cells direct new blood vessel growth. Interestingly the role of Notch in both
tip and stalk cells is evident within the distribution patterns of Notch signaling ligands and
receptors. VEGF signaling induces Dll4 in tip cells, tip cells then suppress tip-cell features in
adjacent stalk cells via Dll4/Notch-mediated lateral inhibition59. Simultaneously Jagged1
antagonizes Dll4-mediated Notch activation in stalk cells to increase tip cell number which
consequently enhances vessel sprouting68. Hence it is this Jagged1 and Dll4 “salt-and-pepper”
pattern that dictates the tip-stalk cell phenotypes within this niche. The function of Notch signaling
varies greatly depending on the location of the vascular bed and also the type of the vessel. The
arteriovenous specification is established early in development through a variety of transcription
factors. A key Notch-defining factor in this specification is the Notch3 receptor found in arterial
SMCs, which is notably absent in veins, and Jagged1 expression by ECs are responsible for this
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maturation. The transcription factors Foxc1 and Foxc2 and VEGF signaling are primarily
responsible for arterial fate61,69; the upregulation of these transcription factors results in increased
expression of Dll4. In contrast, vein identity is regulated by the repression of Notch161.

Figure 2-6 Roles of Notch signaling in the vasculature.
Some major roles in the vasculature, including A) Tip stalk cell patterning utilizing Dll4, Jagged1
signaling, and B) Phenotype control of vascular smooth muscle cells through Jagged1 lateral
induction.
Recruitment of mural cells (VSMC and pericytes) and the formation of a fully
endothelialized lumen are hallmarks of arterial vessel maturation during development61. Upon
activation of Notch in VSMC, ligand-receptor signaling is initiated throughout the VSMC lamellae
by the process of lateral induction (Fig. 2-6 B). The propagation of Notch signaling is crucial for
regulating VSMC phenotype throughout the vascular wall, and hence is a critical phenomenon for
inducing differentiation of the complete VSMC layer toward the homeostatic contractile
phenotype70. Notch3 targeting is more prominent for SMC control and differentiation52,71,72.
Notch1, in contrast, has been shown to regulate EC metabolism, proliferation, and monolayer
regeneration73. Communication between ECs and SMCs in the vascular wall is essential, thus
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diminished Jagged1 expression in ECs leads to abnormal smooth muscle development. Endothelial
expression of Jagged1 is required for activation of Notch3 on VSMC maturation, differentiation,
and contraction74.
The impact of physiological forces within the vascular system on Notch signaling becomes
apparent when considering the ability of the endothelium to respond to force patterning. ECs
modulate their Notch component expression in response to hemodynamic forces. For instance,
Notch1 activation in EC is sensitive to blood flow, where high shear stress has a critical role in the
acquisition and maintenance of arterial indentation via its role in endothelial quiescence75. The
indication that EC appears to respond to predetermined arterial or venous patterns is evident
through current research, and there is a certain level of plasticity cues of the local niche suggested
to be imposed by physical forces, such as hemodynamics76. Taken together, ligand specificity and
selective Notch activation regulate differential phenotypes and function within the vascular
tissue70,77,78. Understanding the tissue distribution of Notch signaling components is highly
relevant to translate them into tissue engineering and regenerative medicine strategies.
Both ECs and SMCs have been implicated in arterial injury and disease states linked to
dysregulation of various signaling pathways, including the Notch signaling pathway. It has been
shown that upon arterial injury in the SMCs, Notch receptors and ligands as well as Notch
transcription factors (HERP and HES) were coordinately downregulated after arterial injury79.
Loss of function of these various ligands and receptors caused by trauma can create distortions in
the microenvironment, where specific cellular fates can be dysregulated. The communication
between SMCs and ECs within the vascular wall is important to control the proper function of the
vasculature. Events such as disruption of the endothelial monolayer, growth factor exposure,
interactions with the extracellular matrix, injury/wound healing, and vascular remodeling can
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cause cascades in VSMC response leading to a rapid downregulation of contractile proteins and
developing a highly proliferative and migratory phenotype6.
Specific to this research, Atherosclerosis has been directly linked to Notch signaling
dysregulation. Atherosclerotic lesions have been speculated to develop in arteries characterized by
disturbed blood flow and low shear stress15,80,81. Lower levels of Notch signaling components were
found in atheroprone regions, suggesting that disturbed blood flow could predispose those areas
to atherosclerosis by affecting Notch signaling74. Additionally, characterizing gene expression
profiles from plaque material in peripheral artery disease patients confirmed the role of Notch in
atherosclerotic plaque stability, including stable or inflamed plaque gene expression profiles linked
to Jagged1 and Dll4 expression in the plaque74. The phenotype switch from a contractile to
proliferative/synthetic states (as discussed previously) is also a determinant for the development
of atherosclerotic lesions54. Notch has been suggested to mediate activation and counteract transdifferentiation of SMCs as well as protect VSMCs from apoptosis, a major determinant of plaque
instability54,82. Knowing this, Notch signaling has been proposed as a new therapeutic target in
atherosclerosis80, and the incorporation of native cell signaling in biomaterial design could prove
valuable.

2.6. Notch signaling presentation strategies
An increasing need for regenerative medicine and tissue engineering approaches have been
suggested to create functional cell-directing template biomaterials substitutes to recover lost
function within a dysfunctional tissue83. Despite the multicellular nature of tissues, tissue
engineering strategies often focus on seeding the main cellular component of a particular tissue to
scaffolds and culture them for tissue maturation. Given the role of heterotypic Notch signaling in
these tissues, the signal-sending cell (ligand-bearing cell) is often missing. Without endothelial
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signals due to vascular injury, tissue engineering approaches have been proposed to provide the
signal lost by ECs. In a biomaterial system, the strategy of presentation of Jagged1 can affect and
direct cellular response greatly. One strategy is to present it as a soluble factor either by adding it
together with culture media or using a delivery system. The soluble factor can be loaded to a
biomaterial and released either by diffusion or by cleavage, delivering the soluble factor in a
paracrine manner. Although the immobilization of paracrine signaling ligands to biomaterial
surfaces is common, it is not required from a signaling point of view, it has been proved to slow
the release profile and increase cellular accessibility to the delivered ligand/protein. The role of
soluble Notch signaling is context-dependent and cell type-dependent.
Embedded and immobilized delivery of Notch ligands via a biomaterial surface facilitates
juxtacrine cell-cell signaling found in the native tissues. Engineered biomaterials can be introduced
to take on the role of the signal-sending cell and act as cell-surrogate biomaterials to replicate the
cell-cell contact needed for signal propagation. Additionally, immobilized delivery allows for
better spatial and temporal control. In general, signaling molecules can be presented to cells in one
of three ways: i) adding them as a soluble factor, ii) direct conjugation or conjugation via a flexible
molecular arm to a scaffold, iii) and affinity immobilization to the scaffold through antibodybinding proteins. The majority of research does allude to the need for ligands anchored or attached
to a surface to effectively activate Notch signaling. The use of various soluble and immobilized
factors can therefore influence Notch signaling and will be discussed.

2.6.1.

Soluble factors to control Notch signaling
Various paracrine signaling factors including soluble Notch ligands, engineered decoy

ligands84, monoclonal antibodies (mAbs)85,86, gamma-secretase inhibitors (GSIs)87,88, and other
soluble growth factors have been used to modulate Notch signaling. Engineered decoy ligands and
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mAbs are potentially advantageous due to their specificity allowing for the targeting of individual
Notch receptors. However, soluble Notch delivery and GSIs are more commonly used in treatment.
Targeting via GSIs stop the release of Notch from the plasma membrane and the subsequent
generation of the NICD. GSIs are intended to reduce the activity of Notch signaling and inhibit
downstream effectors. GSIs can be delivered with or without a biomaterial carrier and can be used
to therapeutically target and control ligand/receptor distribution and adverse cellular responses.
Likewise, soluble Notch ligands function through a paracrine manner (one cell secretes a
ligand that can bind to nearby cells and induce a response). Inherently, bound and soluble Notch
ligands compete for the available Notch receptors on the surface of a nearby cell. Soluble ligands
can bind to Notch receptors but are, for the most part, unable to activate signaling; they rather
appear to block signaling induced by trans-ligands in most cases89. Although soluble ligands have
controversially activated Notch signaling, most commonly soluble Notch ligands have been
applied to cell-based systems to competitively inhibit the Notch receptor active site. As it pertains
to this thesis, the use of soluble Jagged1 to control cell behavior is reviewed in Table 2-2. As
presented in this table, the influence of soluble Notch delivery is very context-dependent. Upon
investigation, the use of soluble Jagged1 in the vascular seems to play an inhibitory role, inhibiting
proliferation and neointima formation but should be explored further.
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Table 2-2 Modulation of Notch signaling using soluble Jagged1

Multipotent
Cells

Primary
Cells

Cell Lines

Cell Type

Function

Role

Ref.

Rat MSCs

MSC differentiation into
cardiomyocytes

Notch
Activation

90

Peripheral blood
Monocyte differentiation into M1,
mononuclear cells Mϕ with antimicrobial activity

Notch
Activation

91

Bone marrowderived dendritic
cells

Maturation and differentiation of
dendritic cells

Notch
Activation

92

Placenta-derived
MSCs

Increased placenta-derived survival
and chondrogenic differentiation

Notch
Inhibition

93

Pulmonary artery
SMCs

Inhibit proliferation, improved
pulmonary hypertension

Notch
Inhibition

94

Cochlear cells

Promotes cochlear sphere formation
and sensory potential

Notch
Activation

95

Coronary artery
SMCs

Inhibition of neointima formation
and enhanced re-endothelialization,
suppressed proliferation and
migration

Notch
Inhibition

96

Human foreskin
keratinocytes

Maturation and differentiation of
human keratinocytes

Notch
Activation

97

NIH3T3
fibroblast

Suppressed tumor onset and growth,
vascularization

Notch
Inhibition

98

3T3-L1 adipocyte
progenitor cell
line

Mature adipocyte differentiation and
proliferation

Notch
Inhibition

99

MSCs- mesenchymal stem cells ; SMCs- smooth muscle cells.
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2.6.2.

Immobilized Notch ligand delivery
Due to the suspected need for anchorage to a cell or biomaterial surface, various

immobilization strategies have been investigated; these include covalent immobilization, infinity
immobilization, and immobilization through a flexible spacer arm. Covalent immobilization
assures ligand presence, but the active site of the ligand is not always accessible for binding due
to this random attachment to the surface. Therefore, Notch orientation-regulated immobilized
scaffolds have been engineered using indirect affinity immobilization strategies and are the most
commonly used in Notch signaling biomaterials. Antibody binding proteins such as Protein A/G,
Streptavidin/Biotin binding, as well as anti-Fc antibodies, have been harnessed to control ligand
accessibility and orient the ligands with the active site available for binding. Compared to covalent
immobilization strategies, affinity binding strategies allow indirect immobilization, but the active
site is oriented controllably for maximized receptor binding capability.
Lastly, immobilization through a flexible molecular arm has been suggested to allow for
better accessibility and activity of the immobilized ligand. Optimal ligand surface coverage can be
maximized with spacers due to the ability of the polymer-bound proteins to form a layer and
disperse the ligands in space to optimize binding and minimize lateral repulsions100. To mimic the
dynamic regulation of signaling ligands, polymer chemistry can be harnessed to create chemical
spacers to improve biomolecular recognition, ligand accessibility and increase the dynamic
behavior of immobilization101.
A summary of Jagged1 immobilized biomaterials for vascular tissue engineering
applications is shown in Table 2-3. Considering its role in multiple tissues, Jagged1 has been
immobilized for bone tissue engineering as well as many other tissue engineering applications
(summarized in Appendix A2: Jagged1 biomaterial immobilization).
26

Table 2-3 Prior studies about immobilized Jagged1 for vascular tissue engineering
Authors

Year

Journal

Cell Type

Application

HES1

HEY1

Ligands

Benedito et al

2009

Cell

human
umbilical
vein ECs

tip-stalk cell
selection

↑

↑

↑ Dll4

Xia et al.

2011

Biomaterials

human
coronary
artery SMCs

phenotype
control

Boucher et al.

2011

Journal of
Biological
Chemistry

aortic SMCs

phenotype
control

Bhattacharyya
et al,

2014

Tissue
Engineering
Part A

human
coronary
artery SMCs

phenotype
control

Boopathy et
al, 2014

2014

Biomaterials

cardiac
progenitor
cells

vascular
differentiation

DavisKnowlton et
al

2019

Laboratory
Investigation

carotid artery
SMCs

phenotype
control

DavisKnowlton et
al

2019

Laboratory
Investigation

diseased
carotid artery
& femoral
artery SMCs

diseased
phenotype
recovery

Putti et al

2019

ACS Omega

human
coronary
artery SMCs

phenotype
control

↑

↑

Putti et al

2019

Applied
Polymer
Materials

vascular
SMCs

phenotype
control

↑

↑

Receptors

Acta2

SM22!

Calponin

Myh11

Ref.
77

NS

NS

↑

↑

NS

↑

NS

53

↑

102

NS

52

↑

↑

103

↑ Notch3

↑

NS

72

↑ Notch3

NS

NS

72

↑Jagged1

↑ Notch3

↑

↑Jagged1

↑ Notch3

↑

104

105
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2.7. Modulation of the Notch signaling pathway
For Notch signaling modulation, the understanding of ligand-receptor specificity is
necessary to utilize developmental biology as inspiration for engineered tissues47,106–108. For
example, the application of synthetic biology can be applied to distinguish between ligand-receptor
affinity vs. avidity between various Notch ligands and receptors107. Nevertheless, insights into
Notch modulation by analyzing the distribution and expression profiles of Notch ligands/receptors
can be crucial because they vary significantly among cell types and behave uniquely to their
surrounding microenvironments34. Within the context of this thesis the Jagged1-Notch3 pairing
has been targeted for vascular applications and SMC control.
Additionally, pathway modulation occurs through the cis- and trans- ligand-receptor
interaction distinction107,109. The balance between cis-inhibition, trans-inhibition, and transactivation can help determine Notch-based decisions. Still, this regulatory mechanism is often
overlooked as it is challenging to uncouple cis- and trans-binding properties in vivo110. While the
response to trans-activation is gradual in response to external ligand signals on neighboring cells,
cis-inhibition is a sharp immediate response, silencing when a level of intracellular ligand exceeds
a threshold concentration111. In addition to the signaling mechanism, signaling range, cell shape,
and packing geometry are also suggested to be a factor in Notch modulation112113. Biologically,
the factors mentioned above play a role in the development and maintenance of various organs,
tissues, and systems within the body. Both two-dimensional and three-dimensional
microenvironments can be used to gain insight into various instructional cues apart from ligand
presentation, including biomaterial cues, spatial cues, temporal cues, mechanotransduction. These
cues to control Notch signaling and influence biomaterial design have been recently reviewed and
published by this author114.
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2.7.1.

Notch signaling as a cofactor and signaling crosstalk
In addition to the canonical Notch pathway, there is also increasing evidence that the Notch

signaling pathway can be activated and modulated without its prominent role as a transcriptional
cofactor115. It is speculated that some of the effects of Notch signaling are due to undiscovered
noncanonical interactions involving various Notch components with components of various other
signaling pathways. Therefore, Notch signaling might have diversity within the pathway, affecting
the activity of other signaling pathways as well as utilizing signals from outside of the Notch
pathway to regulate Notch activity and expression levels. Notch signaling interactions within
VSMCs include Yes-associated protein/ PDZ-binding motif (YAP/TAZ), Platelet-derived Growth
Factorβ (PDGFβ), Transforming Growth Factorβ (TGFβ), Mitogen-Activated Protein Kinase
(MAPK), and Wingless-Related Integration Site (Wnt) (reviewed recently in more detail in
reference115). A summary of crosstalk between Notch and these pathways in the vasculature is
summarized (not exhaustive) in Table 2-4.
Despite the requirement for membrane tethering and endocytosis, the soluble ligand can
activate Notch signaling in non-SEL proteins reported to be noncanonical Notch ligands89. Two
non-DSL proteins have been identified as putative Notch ligands, including connective tissue
growth factor cysteine-rich 61/nephroblastoma overexpressed gene, and microfibril-associated
glycoprotein family-1,2 89.

29

Table 2-4 Notch signaling crosstalk in the vasculature
Pathway

Cell source

Outcome

Ref.

YAP/TAZ

Mouse aortic smooth muscle
cells

Deletion of YAP and TAZ abrogates Notch signaling in
SMCs and impairs development of the aortic arch arteries

116

Mouse aortic smooth muscle
cells

YAP and NICD can physically interact and regulate the
expression of Jagged1

116

Human coronary artery
smooth muscle cells

Notch promotes the transcription of PDGFRb

117

Human aortic smooth muscle
cells

PDGF-B decreases expression levels of Notch2, but not
Notch3 in SMCs

118

Rat aortic smooth muscle
cells

PDGF downregulates Jagged1, Notch3 and HESR-1
expression via an ERK-dependent pathway

119

Human aortic smooth muscle
cells

Induces a molecular and functional contractile phenotype
by co-regulation of Smad activity at SMC promoters
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Human aortic smooth muscle
cells

Jagged1 promotes transcription of miR145 which inhibits
TGFb pathways to cooperatively promote actin and
calponin

102

Human umbilical vein
endothelial cells

BMP9/ALK-1 singling promotes expression of the Notch
target genes Hey1 and Hey2 which inhibits VEGFinduced angiogenesis and vascular morphogenesis

Mouse embryonic
endothelial cells

BMP acts to enhance Notch in endothelial cells to inhibit
migration and limit angiogenesis; increases the
expression of Herp2 through formation of a
transcriptional complex comprised of NICD and Smad
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Differentiated embryonic
stem cells

b-catenin directly associates with and co-activates NICD
forming a transcriptional complex in arterial cells
regulating arterial specification
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Endothelial cells from E9.5
embryos

b-catenin promotes Notch activity inhibits migration in
endothelial cells by binding to the Dll4 promoter and upregulating the transcription of Dll4 increasing Notch
signaling

123

PDGF-B

TGFb

BMP

Wnt
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PDGF-B: platelet-derived growth factor B, YAP/TAZ: Yes-associated protein/ PDZ-binding motif, MAPK:
mitogen-activated protein kinase pathway, Wnt: wingless-related integration site
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An important ligand for this thesis is TGFβ1. TGFβ signaling has been implicated vastly
in the control and differentiation of smooth muscle cells115. Both in vitro and in vivo studies have
shown that TGFβ signaling components are upregulated at the sites of vascular injury, detected
within 6 hours of arterial balloon injury and sustained up to 14 days124. Additionally, TGFβ has
been implicated in ECM accumulation and VSMC proliferation and migration, which are expected
to counter its profibrotic effects125. These varying effects on VSMC are hypothesized to be related
to differential but complementary signaling systems through Smad. The Smad proteins are
classified into three groups; receptor-activated Smads (Smad2 and Smad3), common Smad
(Smad4), and inhibitory Smads (Smad6 and Smad7). At the molecular level, these differences have
been attributed to varying levels of receptor expression, membrane localization of receptors,
availability of intracellular signaling mediators, and presence of transcriptional co-regulators
within the nucleus125. Notch and TGFβ signaling have been identified as co-regulators indicating
cross-talk between these pathways38,126, and has been demonstrated in a liver fibrosis model127.
Specific direct protein interactions have been linked in the two signaling pathways; TGFb
regulated transcription of the HES1 promoter occurs in a Notch-dependent manner, and the NICD
acts cooperatively with Smad2/3115, an intracellular transducer of TGFb signaling as shown in
Figure 2-7.
Activation of Smad2/3 is suggested to induce the activation of synthetic promoters
containing multimerized CSL or Smad3 binding sites. The NICD and Smad3 were shown to
interact directly in a ligand-dependent manner and Smad3 could be recruited to CSL-binding sites
on DNA in the presence of CSL and NICD37. Overall, this could be useful in combination therapy
approaches with promising potential to modulate phenotype control, differentiation, and other
signaling in the vasculature.
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Figure 2-7 TGFb1 Notch signaling crosstalk in VSMC control
The activation of the TGFβ receptor leads to the activation of Smad2/3, which can then
intracellularly form a complex with Smad4124. This complex translocates to the nucleus, where it
can regulate the transcription of target genes by binding to Smad-binding elements. Elements of
Notch signaling can communicate and interact with Smad elements. Upon binding of the Notch
ligand and receptor, the S3 cleavage generates the Notch intracellular domain (NICD) which can
translocate to the nucleus or act cooperatively with Smad2/3 influencing cell behavior.

2.7.2.

Notch and incorporating mechanotransduction forces

Lastly, the modulation of Notch signaling can be driven through mechanical forces. Cells
respond not only to biochemical signals but also to a variety of mechanical forces.
Mechanotransduction is the process of how cells convert a physical force into a biochemical signal.
Cells in the body, and specifically artery walls, undergo a variety of mechanical forces within their
microenvironment, whether it is from contacting cells, the surrounding tissue, or the various bodily
fluids passing through the body. The response of cells to mechanical stimuli and the transmission
of these forces into chemical signals (mechanotransduction) is also important to enhance Notch
signaling efficacy. Cells in the vasculature are subject to various external forces, including strain
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magnitude from blood pressure (upon increased or decreased wall thickening caused by vascular
morphogenesis and phenotype switching)70, and shear stress caused by blood flow (due to cycles
of contraction and relaxation of heart tissue)81,128. Incorporating mechanical signals into
biomaterial in-vitro systems, using bioreactors, or other platforms can allow us to understand the
Notch dynamics in a system and create a better tissue-engineered design.
To further control Notch signaling, there is also evidence that Notch signaling is driven by
cell-cell interactions which are mechanosensitive at the molecular level. Crystal structures have
revealed the overall Notch receptor-ligand conformation indicating that the S2 binding site is
deeply embedded within the Notch heterodimer LNR domain and thus is protected from
metalloprotease cleavage and creates an autoinhibited conformation129,130. The Notch “pulling
model” indicates that the Notch regulatory region of the receptor acts as a force sensor that is
unfolded by a threshold level of mechanical tension generated across the ligand/ receptor bridge
(Fig. 2-8). This tensional force is debated to be caused by the endocytosis force of the ligandreceptor complex, whereby tethering alone without ligand endocytosis was proven to be
insufficient for Notch activation131. Notch in the absence of endocytosis, ligands were shown to
accumulate on the cell surface but fail to activate Notch signaling on neighboring cells 41.
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Figure 2-8 The pulling model for Notch activation
Upon ligand-receptor binding, the Notch receptor must undergo protein unfolding caused by
applying a tension pulling force. A tension force at the ligand-receptor complex pulls the LNR
repeats away from the S2 domain. This allows for the active site to be uncovered and S2 cleavage
of the extracellular domain by ADAM to occur. Published as Kathleen Zohorsky and Kibret
Mequanint. Tissue Eng. Part B. NRR-Notch regulatory region, LNR- Lin12/ Notch related domain
© Copyright 2020, Mary Ann Liebert, Inc.
The role of mechanotransduction within the Notch signaling pathway is still controversial
and a highly debated topic of research currently. Considering these concepts, the interplay between
mechanical force transduction and its interaction with ligand immobilized to the surface of
biomaterials poses another important challenge in the integration of these complex cellular
processes into biomaterial-based systems. Additionally, the delivery of chemical signals via a
biomaterial surface presents the absence of the mechanical tension force found biologically
through the pulling force. When replacing the signal sending cell with a biomaterial surface, it is
questioned whether there is sufficient molecular force (without endocytosis) for signal activation.
Mechanotransduction within Notch signaling thus far has been very context-dependent; therefore,
various ligand-receptor combination could prove to be more mechanosensitive than others. Up
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until recently, ligand-receptor mechanosensitivity has been studied with preference to delta-like
ligands and not Jagged ligands.

2.8. Molecular force recognition and force application
Various tools have been utilized to study the effects of forces on cells, including atomic
force microscopy 132, optical tweezers 133, flow systems, tension gauge tethers (TGTs) 134, as well
as fluorescence resonance energy transfer135,136 tension sensors. However, biochemical analysis is
difficult with many of these techniques. The use of magnetic tweezers 137–144 and magnetic beads
to apply tension to cells readily facilitates both single cell assays as well as bulk chemical assays,
which makes this tool readily used to study mechanotransduction. These force application and
force sensing techniques are visually presented in Figure 2-9 A, B, respectively.

Figure 2-9 Force application and force sensing techniques
A) Force application techniques can be used to measure cell response to an applied deformation
or force and can be propped by various stimulus including cantilever, optical, magnetic, fluid flow,
acoustic, or electrical stimulation. B) Force sensing techniques are used to measure the forces
produced by the cells during development, contraction, migration and other cellular processes.
(Reproduced with permission from ref 145. © Copyright 2013 by ASME)
An important tool that has been implemented to study Notch signaling is TGTs which are
force sensors. ProteinG based TGTs have been frequently used to study the force magnitude
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required for signal activation. Recombinant ligands with IgG-Fc fusion are assembled using DNA
tethers with different tension tolerances immobilized through a glass surface passivated with PEG.
The Notch ligand Dll1 was tethered to the surface and using a reporter cell line, it was determined
that under 12 piconewtons (pN) of force was required for signal activation135. A similar result was
found using another TGT assay
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. Force-induced Notch activation has also been studied at the

ligand-receptor bridge using Notch ligand immobilized to magnetic nanoparticles to form a
magnetic tweezer assay. Magnets have been utilized to apply a range of pN-scale forces to the
Notch receptor on the cell surface, and Dll4-loaded magnetic beads induced Notch signal
activation with the addition of this mechanical tension force131. This further proved that force must
be applied to bead-tethered ligands to further induce the canonical proteolytic steps responsible
for Notch activation. Magnetic tweezers demonstrate a simple and effective strategy to introduce
molecular forces in the pN and should be adapted to demonstrate mechanosensitivity in other
ligand-receptor pairings as a useful way to enhance Notch signaling. These and other studies
suggest Notch signaling activation might require piconewton force application that must be
incorporated into biomaterial design, and thus is an interesting avenue to explore.

2.9. Thesis motivation
Proper communication between ECs and SMCs in the arterial wall is important to maintain
vascular homeostasis and contractile cell behavior. Stenting is a common treatment to reopen an
atherosclerotic artery. However, upon stent deployment, it causes endothelial injury resulting in
reduced function and communication between these cells leading to complications including
restenosis, reduced blood flow and potential heart attack. Many attempts have been made to fix
the complications with stents including drug-eluting stents and biodegradable stents. These have
shown little clinical success in improving restenosis. Functionalizing stent surfaces with a
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bioactive protein such as Jagged1 may enable the stent to act as an endothelial cell surrogate
material to direct EC regeneration, enhance contractile SMC function, and phenotype regulation
of VSMCs. The long-term therapeutic objective of this project is shown in Figure 2-10. This figure
is a schematic of a Jagged1-functionalized stent material used to regain proper arterial function
and cellular communication. Short-term the effectiveness of immobilized Jagged1 delivery
platforms need to be optimized, and insights into modulation of the vascular smooth muscle cell
response are needed for proof of concept.

Figure 2-10 Notch signaling bioactive stent material

2.10. Thesis objectives
This thesis explored the effectiveness of Jagged1 treatment on SMC response in culture to
determine the value of the proposed long-term objective. To test the signaling efficacy of Jagged1
the following specific objectives for this thesis were developed:
(i)

Evaluation of the effect of Jagged1 presentation strategies on coronary artery smooth
muscle cell phenotype control and differentiation
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(ii)

Investigation of iPSC-MSC and 10T1/2 cells for Notch signaling

(iii)

Investigation of Jagged1 mechanotransduction to potentially enhance signaling
efficacy
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Chapter 3. Materials and Methods
This chapter details the methodologies used to direct smooth muscle cell differentiation and
phenotype control utilizing Jagged1 directed Notch signaling.

3.1. Materials
Proteins. Protein G DynabeadsTM were purchased from Invitrogen (Burlington, ON, Canada) to
immobilize recombinant human Jagged1/Fc chimera Protein (1277-JG) which was purchased from
R&D Systems and reconstituted in Phosphate-buffered saline (PBS). For Notch signaling studies,
the Notch inhibitor DAPT was purchased from Sigma. Transforming growth factor-beta 1
(TGFb1) was purchased from Abcam (Cambridge, MA), and Fibronectin (FN) was supplied by
Santa Cruz Biotechnology (Sant Cruz, CA) to promote cell adhesion. Hanks’ Balanced Salt
Solution (HBSS) used for solubilizing FN and washing cells which was purchased from Gibco
(Maryland, USA).
Cells and Cell Culture Media. Cell culture studies were conducted using primary human
coronary artery smooth muscle cells (HCASMCs) cultured in smooth muscle growth media
(SmGM; SmGM®-2 BulletKit) obtained from Lonza (Walkersville, MD). Media was
supplemented with 0.50 mL insulin, 1.00 mL hFGF-B, 0.50 mL GA-1000, 25mL FBS, and 0.5mL
hEGF, as provided in the SmGM-2 SingleQuots Kit. Other cell types used were mouse embryonic
multipotent mesenchymal progenitor cell line (10T1/2 cells) purchased from ATCC and
maintained in Dulbecco’s modified Eagles medium (DMEM) (ThermoFisher) containing 5% fetal
bovine serum (FBS) (Thermo Fisher) and 1% penicillin/streptomycin (ThermoFisher) by volume.
Lastly, iPSC-derived MSCs were a gift by Dr. Dale Laird (Western University, Canada). iPSCMSCs were maintained in Mesenchymal Stem Cell Expansion Media (MSCEM, Cellular
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Engineering Technologies Inc., IA, USA), supplemented with 10% fetal bovine serum (FBS), 1%
l-glutamine and 1% penicillin/streptomycin (all from Life Technologies, Canada).
Additional Materials for Mechanotransduction Studies: Sylgard 184 silicone elastomer prepolymer and the curing agent (PDMS, Part A and B) were used to change the culture well height
of the 96-well plate and was purchased from Ellsworth Adhesive Chemical Co. A plate containing
96 cylindrical magnets used to provide a magnetic force to the Protein G beads was purchased
from Alpaqua Engineering.
Western Blot: The antibodies for use in Western blot (anti-Acta2, anti-Cnn1, anti-Myh11, antiJagged1, anti-Notch3) were purchased from Santa Cruz Biotechnology with the exception of
GAPDH which was purchased from Millipore (Temecula, CA). Protein concentrations were
measured using 660 nm Protein Assay supplied by Thermo Scientific (Ottawa, Canada).
SuperSignal® West Pico Chemiluminescent Substrate was supplied by Thermo Scientific
(Rockford, IL).
RT q-PCR: RNA analysis of HCASMCs was achieved using TRIzol® Reagent and SuperScriptTM
from Invitrogen and a Chromo4 Real-time Thermal Cycler, iQTM SYBR® Green Supermix and
Gene Expression Macro analysis software from Bio-Rad (Mississauga, ON, Canada).
Immunofluorescence: For cell fixation, paraformaldehyde was purchased from EMD Chemicals.
(Gibbstown, NJ). All Alexa-594 conjugated goat anti-mouse and Alexa-594 conjugate goat antirabbit antibodies were purchased from ThermoFisher Scientific. Additionally, the AlexaTM Fluorr
594-conjugated phalloidin to stain F-actin was also purchased from ThermoFisher Scientific. A
Zeiss LSM 510 confocal microscope is from Zeiss, Canada .
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3.2. Cell culture
3.2.1.

Primary human coronary artery smooth muscle cells (HCASMCs)

Primary HCASMCs were cultured in smooth muscle growth media (SmGM). Cell cultures
were maintained in a humidified incubator at 5% CO2 and 37 oC and were used between passages
4-11.

3.2.2.
Human-induced pluripotent stem cell-derived mesenchymal stem cells
(iPSC-MSC)
IPSC-MSCs were grown on gelatin (Sigma-Aldrich) coated dishes in Mesenchymal Stem
Cell Expansion Media (MSCEM). Culture dishes and plates were coated pre-coated with 0.1%
gelatin solution (Signa-Aldrich) for 1 hr. Media were changed every other day for until confluency.
Cell cultures were maintained in a humidified incubator at 5% CO2 and 37 oC and were used
between passages 8-12.

3.2.3.
Mouse embryonic multipotent mesenchymal progenitor (10T1/2) cell
line
Undifferentiated embryonic multipotent mesenchymal progenitor cell line, 10T1/2 cells were
maintained in modified Eagles’ medium (DMEM) containing 5% fetal bovine serum (FBS) and
1% penicillin/streptomycin by volume. 10T1/2 cells treated with 2ng/mL TGFb1 for a period of
three days were used to pre-differentiate these cells towards a vascular lineage. Media were
changed every three days, and cells were passaged when they reached 90% confluency as per
manufacturers recommendations. Both undifferentiated and predifferentiated 10T1/2 cells were
used for future experiments. (Differentiation protocol from ref 2).
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3.3. Jagged1/Fc protein immobilization to Protein G magnetic DynabeadsTM
The maximum binding capacity of Protein G beads provided by the manufacturer states that
100 µL of Protein G DynabeadsTM will isolate approximately 25-30µg of human IgG per a sample
containing 20-200µg/mL. Protein G Dynabeads at a volume of 200 beads/cell were washed 3 times
with PBS (pH 7.4, 0.02% Tween). The addition of 2.5 µg/mL (culture media) of human Jagged1/Fc
chimera protein (original concentration 200 µg/mL) was added to the Protein G bead suspension
and incubated for 10 minutes under rotation at room temperature. To remove the unbound Jagged1
the immobilized beads were washed 3X with PBS. Beads were resuspended in PBS and added to
cell cultures at a concentration of 200 beads/cell. The immobilization scheme is shown in Figure
3-1.

Figure 3-1 Jagged1 immobilization scheme to Protein G beads

3.4. Jagged1 delivery to control smooth muscle cell differentiation and
phenotype control
Cells were seeded in culture dishes and incubated for 48 hours to allow for cell attachment.
Cells were treated with ProteinG beads (200 beads/cell), soluble Jagged1 (2.5µg/mL), or Jagged1
immobilized beads (2.5 µg/mL, 200 beads/cell), to determine the effects of Jagged1 delivery on
SMC response (Protocol adapted from ref 3,4). This was done for HCASMCs and iPSC-MSCs. For

53

10T1/2 cells, the effect of both soluble and immobilized Jagged1 was analyzed for both
undifferentiated and TGFb1 pre-differentiated cells.

3.4.1.

Serum starvation of HCASMC

Cover slides were coated with 0.1% gelatin for 1 hr at 37 oC. HCASMCs were seeded on
coverslips at a density of 2 500 cells/cm2 and cultured until cells reached 50% confluency.
HCASMCs maintained in SmGM were used as controls. HCASMCs were cultured in serum-free
DMEM, and in serum-free DMEM + TGFb1 (2ng/mL) for 72 hours. 10T1/2 cells were then fixed
and stained with anti-calponin1/2/3, anti-smoothelin, and anti-Myh11, and imaged using confocal
microscopy to look at protein expression levels and morphological changes.

3.4.2.

Notch inhibition with DAPT

Cells were plated and cultured for 48-hours and treated overnight with 10µM DAPT (a gsecretase Notch inhibitor). The spent media was aspirated and replaced with fresh media, and cells
were treated with an additional 10µM DAPT ± Jagged1 immobilized beads (2.5µg/mL,200 beads/
cell). The DAPT inhibition assay was performed for HCASMCs, iPSC derived MSCs, and predifferentiated 10T1/2 cells. Cells cultured alone were used as controls for these experiments.
Expression of downstream gene and protein targets were done by RT-qPCR, Western Blot, or
immunofluorescence microscopy.

3.4.3.

Notch and TGFb crosstalk

To examine the effects of Jagged1 and TGFb1 ligands on SMC response, HCASMCS were
plated in 24-well culture dishes at a seeding density of 50 000 cells/ well and cultured for 48 hours
to allow for cell spreading and cell attachment. Cells were treated with i) Jagged1 immobilized
beads (2.5µg/mL, 200 beads/cell) ii) Jagged1 immobilized beads (2.5µg/mL, 200 beads/cell) +
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DAPT (10mM) iii) TGFb1 (2ng/mL), iv) TGFb1 (2ng/mL) + DAPT, and v) Jagged1 immobilized
beads 2.5µg/mL + TGFb1 (2ng/mL). All cell treatments were done for a 3-day timeframe. DAPT
was used to determine Notch specific response, and the combination treatment was used to
demonstrate potential crosstalk between the two signaling pathways. Cells cultured alone were
used as controls for these experiments. The cell response was analyzed by qPCR.

3.5. Exploring Jagged1 mechanotransduction to potentially enhance signaling
efficacy
HCASMC’s or pre-differentiated 10T1/2 cells were seeded in a 96-well plate at a seeding
density of 10 000 cells/well and cultured for 48 hours to allow attachment and cell spreading. Cells
were cultured for 12 hours with the addition of immobilized Jagged1 (2.5 µg/mL, 200 beads/cell).
Cells were left overnight to allow for receptor-ligand binding, then a multiplexed cylindrical
magnet plate (Fig. 3-2 A) was positioned over the 96-well plate of cells (1 magnet per well). This
applied a tension force to the magnetic beads bound to the Notch3 receptors on the signal receiving
smooth muscle cell (Fig. 3-2 B). Cells were cultured for 3 days before cells were analyzed with
RT-qPCR. Results were compared to cells in the presence of Jagged1 immobilized magnetic beads
without the application of a magnetic tension force, and cells without the Jagged1 beads ± the 96well magnet (Protocol adapted from 6)

55

A

B
Force

Protein G Magnetic
Dynabead

Jagged1-Fc
Notch3 Receptor

C

cell surface
NICD

nucleus
Cell Response

Figure 3-2. 96-well magnetic tweezer setup.
A) 96 well cylindrical magnet plate set-up. B) Force application to magnetic DynabeadsTM tethered
to Notch receptors on the smooth muscle cell surface, and subsequent ADAM S2 cleavage
(Adapted with permission from ref 5 Copyright © 2016, Springer Nature, and ref 6, Copyright ©
2015 Elsevier Inc.) C) Terraced magnet configuration with PDMS Polymer to control force
magnitude. (Reproduced with permission from ref 6, Copyright © 2015 Elsevier Inc.).
In order to explore various piconewton force magnitudes, the distance between the cells and
magnet was varied using PDMS polymer to create terraces of different heights (Fig. 3-2 C)
(Protocol was adopted from ref 6). PDMS of various volumes, 0 µL, 60µL, 90µL, 120µL were
dispensed into a 96 well plate (increasing the height increases the tension force applied on the
ligand-receptor complex). PDMS surface was sterilized with 70% ethanol at RT for 1 hr, followed
by FN adsorption for 1 hour at 5 µg/cm2. Cells were plated at a density of 10 000 cells/well and
cultured for 48 hours to allow for cell attachment and growth. Next cells were treated with
Jagged1-immobilized DynabeadsTM (2.5 µg/mL, 200 beads/cell) for 12 hours. After 12 hours, the
magnet plate was added on top of the culture dish and cultured for an additional 48 hours.
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HCASMC cultured alone, and HCASMCs cultured with Jagged1 immobilized DynabeadsTM
without a magnet lid served as controls.

3.6. RNA isolation and quantitative real-time quantitative polymerase chain
(RT-qPCR) analysis
Total RNA was isolated from 2D cell cultures using TRIzol. Spent media was aspirated and
1 mL TRIzol per 10 cm2 was used per treatment group to collect cells using TRIzol reagent
(Invitrogen, USA). Cells were pipetted several times to form a homogenous lysate then were left
at room temperature for 10 mins to allow for complete dissociation of nucleoprotein complexes.
500µL of chloroform was added, vortexed for 15 sec, then incubated at RT for 15 min. The samples
were centrifuged at 12,000 x g for 15 min at 4oC. The organic phase was discarded, and the aqueous
phase was transferred to a fresh 2mL Eppendorf tube. Isopropanol was added at a ratio of 1:2
(isopropanol: TRIzol) and incubated at RT for 10 mins followed by centrifugation at 12,000 x g
for another 10 mins at 4oC. Isopropanol was then aspirated from the Eppendorf tube, and the RNA
pellet was resuspended in 1 mL of 75% EtOH. Lastly, the suspended pellet was centrifuged 7500
× g for 5 min at 4 °C. EtOH was aspirated and the RNA pellet was air-dried for 10 mins in the
fume hood. The RNA pellet was dissolved in 25 μL of DEPC water and quantified with the
Nanodrop reader (Thermo Scientific). 1 μg of total RNA was used to synthesize cDNA using MMLV reverse transcriptase kit (Promega) using the supplier’s protocol. Reverse transcription was
performed as per the manufacturer’s instructions.
To prepare RT-qPCR reactions, 1 μL of cDNA was used per 10 µL reaction using the
SsoAdvanced universal SYBR green Supermix (Bio-Rad) according to the manufacturer’s
protocol. Quantitative real-time PCR was conducted in 10 uL reaction volumes, using a Chromo4
Real-time Thermal Cycler, and gene expression of human Jagged1, Notch3, HES1, SM-a-actin
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(Acta2), calponin (Cnn1), myosin heavy chain (Myh11) and glyceraldehyde- 3-phosphate
dehydrogenase (Gapdh, reference gene). Gene expression was then determined with iQTM
SYBR® Green Supermix according to the recommended manufacturer protocol. For HCASMCs
and iPSC-MSC cells, human-specific (Table 3-1) forward and reverse primer sequences were used
for amplification. Furthermore, for 10T1/2 cells, mouse-specific forward and reverse primer
sequences (Table 3-2) were used for amplification. The RT-qPCR reactions were carried out in a
CFX96 Real-Time thermal cycler (Bio-Rad) and Gapdh was used as a reference gene.
Table 3-1.Primers for human-specific mRNA amplification.
Gene

Forward Primer (5’® 3’)

Reverse Primer (5’® 3’)

HES1

GCACAGAAAGTCATCAAAGCC

CGCGAGCTATCTTTCTTCAGA

Acta2

CAAGTGATCACCATCGGAAAT G GACTCCATCCCGATGAAGGA

Cnnl

TGAAGCCCCACGACATTTTT

Myh11 GACCAGGATCTCATCCTCCA

GGGTGGACTGCACCTGTGTA
AGCAGCTACAGGCTGAAAGG

Gapdh GGTGGTCTCCTCTGACTTCAACA GTTGCTGTAGCCAAATTCGTTGT
Acta2- smooth muscle-a-actin; Cnn1- calponin; Myh11- smooth muscle myosin heavy chain 11

Table 3-2 Primers for mouse-specific mRNA amplification.
Gene

Forward Primer (5’® 3’)

Reverse Primer (5’® 3’)

Jagged1

TGCGTGGTCAATGGAGACTCCT

TCGCACCGATACCAGTTGTCTC

Notch3

GGTAGTCACTGTGAACACGAGG

CAACTGTCACCAGCATAGCCAG

HES1

GGAAATGACTGTGAAGCACCTCC GAAGCGGGTCACCTCGTTCATG

Acta2

GGGCTATATAACCCTTCAGCG

GCTGTCTTCCTCTTCACACAT

Cnnl

ACTGGGTACAGATCAGCCTCT

TAGGCAGAGTTGTAGTAGTTG

Myh11

CTGGTTACATTGTAGGTGCCA

GCGAGCAGGTAGTAGAAGATG

Gapdh

AAGGGCTCATGACCACAGTC

GTGAGCTTCCCGTTCAGCTC

Acta2- smooth muscle-a-actin; Cnn1- calponin; Myh11- smooth muscle myosin heavy chain 11
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3.7. Immunofluorescence microscopy
For immunofluorescence imaging, cells were seeded on either 6-well plates containing a
circular coverslip (area 1.9 coverslip cm2), or a 35mm culture dish containing 2 square coverslips
( area of 1.9 cm2). Coverslips were sterilized using ethanol. Fibronectin (FN) was diluted in HBSS
to a desired concentration of 5µg FN/cm2 and absorbed onto coverslips for 1 hour at room
temperature to improve cell attachment. After 24 h, HCASMCs, or 10T1/2 cells were treated with
various treatments as described in the protocols above. After treatment for 72 hours, cells were
washed with PBS and fixed using a 4% solution of paraformaldehyde for 30 mins at room
temperature. Next, cells were permeabilized in 0.5% (v/v) Triton X-100 in PBS for 15 min and
washed three times with 1x PBS. Finally, cells were blocked with 5% BAS in PVS-T for 1 hr.
Blocking solution was aspirated and 100 uL of the appropriate antibodies (mouse anti-Acta2
(1:100), mouse anti-calponin1/2/3 (1:100), rabbit anti-smoothelin, (1:100), mouse anti-Myh11
(1:100)) in 5% BSA PBS-T covered overnight at 4 oC. Cells were washed 2X with PBS-T and 1X
with PBS, and then primary antibody binding was detected by incubating cells with the
corresponding secondary antibody (Alexa-488 conjugated goat anti-mouse and Alexa-594
conjugated goat anti-rabbit (1:150)) in 5% BSA PBS-T for 1 hr. at RT. 4′,6-Diamidino-2phenylindole (DAPI; 300 nmol in PBS) was used to visualize cell nuclei, was used and F-actin
was stained with Alexa™ Fluor 594-conjugated phalloidin (1:100). Images were taken with a Zeiss
LSM 510 confocal microscope (Zeiss, Canada) equipped with an argon/neon as well as a UV
laser. Quantification of the fluorescence intensity was performed using the ImageJ software. The
target protein was quantified and normalized to the control.
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3.8. Western blotting
Western blot was used to look at protein expression levels of Jagged1, Notch3, SM-a-actin,
and calponin in 2D cultures. Cells were washed 3X with 1mL/well of ice-cold phosphate-buffered
saline (PBS), and then harvested with 150 µL/well of ice-cold NP-40 Lysis buffer with protein
inhibitor to extract whole cell lysate. Cells were kept on ice for 15 mins to allow for complete cell
lysis. The cell suspension underwent three freeze-thaw cycles in the -80oC freezer. Lysates were
micro-centrifuged at 12 000 RPM for 15 mins. The pellets were discarded, and the total protein
concentrations found in the supernatant were determined using a Pierce BCA protein 562nm
colorimetric protein assay according to the manufacturer’s instructions.
Twenty micrograms per well of protein was loaded and separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for 60 min and then subsequently
transferred onto a nitrocellulose membrane. Ponceau S stain was used to verify the proper protein
transfer to the membrane, then was washed with DI water to de-stain the membrane. Membranes
were blocked with 5% nonfat dry milk in 1XPBS for 1 h and then incubated in primary antibodies
diluted in 5% nonfat dry milk in 1×PBS. The membrane was incubated for 2 h with primary
antibodies, which included anti-SM a-actin (1:1000 dilution), anti-calponin (1:1000 dilution),
anti-Jagged1 (1:200 dilution), anti-Notch3 (1:200 dilution), anti-GAPDH (1:2000 dilution,
reference gene), all from Santa Cruz, Inc. Next the membrane was incubated with horseradish
peroxidase-conjugated secondary antibodies for 1 h. To image the membranes, they were
incubated for 5 min in SuperSignal®West Pico Chemiluminescent substrate. Bio-Rad’s
ChemiDocTM XRS+ System was used to image the membranes and blots were quantified using
Image LabTM software.

60

3.9. Statistical analysis
Data are presented as the relative means ± SD and normalized to the experimental control of
cells plated alone. Statistical significance was calculated either using student’s t-test or one-way
ANOVA followed by Tukey’s post hoc test to compare differences between groups. Values of
p<0.05 were considered to be statistically significant.
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Chapter 4. Results and Discussion
This chapter presents and discusses the results of various experiments to evaluate the influence
of Jagged1 on the control of vascular smooth muscle cells.

4.1. Jagged1 directed control of Notch activation and phenotype control in
HCASMCs
In this study, the effect of Jagged1 on smooth muscle cell phenotype control driven through
the Notch signaling pathway was studied. Notch signaling has been suggested to control both
developmental and mature vascular tissue; specifically, the Notch ligand Jagged1 has been proven
to drive phenotypic modulation in smooth muscle cells1–3. Jagged1 a Notch ligand, is a
transmembrane protein expressed predominately in vascular ECs in the arterial wall1,4. The
activation of the Notch3 receptor by Jagged1 maintains an autoregulatory, positive feedback loop
by which Jagged1 robustly induces Notch3 expression to maintain a differentiated phenotype5.
The Notch receptor-ligand family and domain organization of the proteins are shown in Figure
4-1.
As previously determined, endothelial cell-bound Jagged1 has shown promising results in
coculture models to control the contractile phenotype of HCASMCs3,6,7. Furthermore, endothelialspecific knockout of Jagged1 has resulted in improper embryonic development and the absence of
smooth muscle gene expression in the vasculature1. Given that Notch signaling is suggested to be
driven by contact specific cell-cell communication, one goal of the study was to recapitulate the
EC-SMC relationship by developing a bead-based EC-surrogate.
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Figure 4-1 Domain organization of Notch ligands and receptors.
A) Notch receptor domain organization B) Notch DSL ligand domain organization C)
Recombinant Jagged1 domain organization. TM- transmembrane, LNR-Lin-12/Notch repeat, HDheterodimerization domain.
From a tissue engineering or therapeutic perspective, soluble Jagged1 could be delivered
to cells via the culture medium if it induces HCASMCs contractile phenotype. In contrast,
immobilized Jagged1 delivered via surface immobilization to biomaterials or beads may also be
an approach to produce a significant influence on cell contractile phenotype driven by Jagged1Notch3 signaling. The rationale behind surface immobilization rather than embedded delivery is
that the bead surface could potentially mimic the signaling cell surface by presenting Jagged1 to
adjacent HCASMCS and allow for direct cell-bead contact. Furthermore, this may allow proper
cellular pulling or traction forces needed for Notch activation. Table 4-1 provides a summary of
the use of Jagged1 bead immobilization to direct cellular responses. This thesis will focus on
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Jagged1 presentation strategies, including both soluble and bead immobilized delivery of Jagged1
to direct and control SMC phenotype.
Table 4-1 2D immobilization strategies of Notch ligands to microbead systems
Platform

Immobilization
Method

Notch
Ligand

Application

Cell Type

Ref.

Dll4

Hematopoietic
differentiation into T
cells, myotube
inhibition

C2C12
(mouse)
myoblasts

8

Dll4

Micropatterning
angiogenesis

HUVECs

9

Jagged1 Smooth muscle cell
differentiation and
phenotype control

Human
coronary artery
smooth muscle
cells
(HCASMCs)

6,7

Jagged1 Osteogenic
differentiation

Human MSCs

10

U2OS cell line

11

Human
embryonic
stem cells
(hESCs)

12

Biotin Linker

Protein G
Bead
Immobilization

SNAP Tag
Sequence

Dll1

Force activation of
Notch receptors

Jagged1 Biphasic effect on
cardiac
EDC/NHS +
differentiation,
antipolyhistidine
ectodermal
differentiation

4.1.1.
Jagged1 presentation strategies for HCASMC differentiation and
phenotype control.
HCASMCS were cultured for 36 hours in media containing 2.5 µg/ml soluble Jagged1 or 2.5
µg/ml immobilized Jagged1 (200 beads/cell). Protein G beads at a concentration of 200 beads/cell
were used as a control to account for any nonspecific effects of Protein G on HCASMC response.
Protein G was selected as the immobilization method because it allows controlled immobilization
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of recombinant proteins through the Fc domain of the ligand, which would orient Jagged1 with the
active site available for binding. Although affinity immobilization forms a non-covalent bond
trapping the ligands to the surface using various proteins, the binding strength of Protein G (kd~
10-10) is sufficient to withstand cellular forces that may break the bond, thus stable in culture
conditions. Orientation-regulated immobilization enables to optimize the number of ligands
available on the surface for binding to Notch receptors. The maximum capture efficiency of Protein
G is approximately 0.25 µg human igG per 1µL bead volume, in its original bead concentration
(as provided by the manufacturer). To immobilize Jagged1 to the bead surface, recombinant
Jagged1 was incubated with ProteinG magnetic DynabeadsTM under rotation for 10 min at room
temperature.
Previously studies suggested that SMC were not responsive to the IgG control which accounts
for non-specific effects of the Fc-fragment found on the Jagged1 protein 6,7. In order to assess the
role of soluble and immobilized Jagged1 stimulation on HCASMC Notch3 signaling, multiple
smooth-muscle cell markers were measured and analyzed (Figure 4-2), including HES1 a Notch
transcription factor and contractile SMC markers SM-a-actin (Acta2), Calponin (Cnn1) and
Myosin heavy chain (Myh11).
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Figure 4-2 Immobilized Jagged1 upregulates Notch transcription factor and early-stage
smooth muscle cell contractile markers in HCASMCs.
HCASMCs were cultured for 2 days in 24 well plate, and then incubated for 3 days with i) soluble
Jagged1 (2.5µg/mL), ii) Protein G beads (200 beads/cell) or iii) immobilized Jagged1/Fc beads
(2.5µg/mL, 200 beads/cell). Expression levels of A) HES1, B) Acta2, C) Cnn1, and D) Myh11 of
3 independent studies were quantified by RT-qPCR and compared to untreated HCASMC cultures
in SmGM (represented as the control). Jagged1 immobilized beads were able to upregulate the
expression of both the transcriptional factor HES1 and contractile marker genes Acta1 and Cnn1,
with no significant effect on Myh11. Data are represented as mean ± SD, normalized to the control.
* indicates significance p < 0.05.
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4.1.1.1. Soluble Jagged1 delivery on smooth muscle cell response
Although delivery of soluble Notch ligands primarily acts as an inhibitor of the Notch
signaling pathway13–19, its delivery has been therapeutically useful in certain applications to control
cell fate decisions20–24 (refer to Table 2-2, Section 2.6.1). With support from the literature, the data
suggests that the addition of soluble Jagged1 into HCASMC cultures did not significantly affect
the expression of HES1 or any smooth-muscle contractile markers measured (Fig. 4-2 A-D). Since
soluble Jagged1 failed to upregulate SMC contractile marker genes, it is reasonable to infer that
similarly to cis-ligand interactions which are inhibitory, soluble Jagged1 also may not be able to
activate Notch3 receptors. This may be attributed to the lack of cellular force available at the
ligand-receptor complex to create the conformational change and expose the S2 cleavage site26.

4.1.1.2. Immobilized Jagged1 delivery on HCASMC gene expression
Since soluble Jagged1 was insufficient to induce SMC contractile function, immobilized
Jagged1 was investigated. The immobilization of Jagged1 significantly enhanced the transcription
factor HES1 as well as early and mid-stage SMC contractile markers SM-a-actin (Acta2) and
Calponin (Cnn1). Results from Figure 4-2 A indicate a significant upregulation in the presence of
Jagged1 beads (p<0.05). These results support that activation of the Notch signaling pathway was
driven in response to bead-bound Jagged1. HES1 expression is caused when the intracellular
domain of Notch3 is released from the plasma membrane post S3 cleavage. The association with
RBPJ causes conformation changes of proteins within the nucleus which also for co-activators to
bind, and this new activating complex promotes HES1 expression. Consistent with previous
studies where immobilized Jagged1 significantly upregulated Notch3 gene expression7, the current
study provides additional support for the upregulation of contractile gene markers. Gene
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expression of early/mid-stage SMC contractile markers, Acta2, and Cnn1 were also upregulated
(Fig. 4-2 B, C).
SM-a-actin (SMA, Acta2) has been previously linked as a direct target of Notch/CSL
domain; CSL directly binds to a conserved cis-element in the SMA promoter and this is required
for Notch-mediated SMA induction27. From this study, Cnn1 also seems to be linked with the
Notch signaling pathway directly. A HES1 site in the promoter of the Cnn2 isoform of calponin
has been associated as a tension-regulated (substrate stiffness) repressor responsive to Notch
signaling28. Additionally, other studies have postulated that Notch induction of Cnn1 is dependent
on Notch-CBF1 activity29.
Lastly, myosin-heavy chain expression (Myh11), a late-stage contractile marker, was not
significantly affected in these cells over a 3-day culture period (Fig. 4-2 D). This marker has not
been linked as a direct target of Notch signaling in the literature thus far for vascular smooth
muscle cells. Longer culture times should be investigated in the future to determine if SMCs in an
extended Jagged1 activated state may start to produce later stage contractile marker myosin heavy
chain. Overall, this data (Fig. 4-2) suggests that to mimic the proper cell-cell communication
needed for Notch signaling, driven by juxtacrine interactions, the immobilization of Jagged1 to a
surface is needed. Therefore, it is suggested that immobilization can provide the structural cues
necessary for HCASMC Notch activation and phenotype modulation.
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4.1.1.3. Jagged1 immobilization concentration dependence of HCASMCs
Because Notch signaling is stoichiometrically driven rather than enzymatically driven, there
is likely a concentration dependency of Notch signaling on cell response. The concentration/dose
dependence and time-dependent response of cells have been shown for stem cell osteogenic
differentiation10,30, and cochlear stem/progenitor sphere formation24. However, dose-response
seems to be context-dependent. Previously Jagged1 concentration dependence on HCASMCs was
not seen6 while dose dependency has been demonstrated for other Notch ligands such as Dll131.
Thus, the influence on Jagged1 concentration was investigated further. Based upon the literature,
there is a wide range of Jagged1 concentrations for bead immobilization ranging from 0.5-10 µg
per sample immobilized in 100 uL-150uL bead volumes per treatment group9.
In this study, the bead volume was kept constant at 20 µL Protein G xbeads and 0-5 µg of
Jagged1 was immobilized to the bead surface and subsequently cultured with HCASMCs. An
ELISA assay was used to determine total immobilized protein by using the bead wash fractions
and measuring the total protein that is not immobilized to the bead surface (Figure 4-3 A). The
protein measured in the wash fraction was then subtracted from the total protein concentration
added to determine the total protein amount immobilized to 20 µL of beads. As per the
manufacturer’s instruction, 5 µg is the maximum concentration per this specific volume. We did
not reach the maximum binding capacity (Figure 4-3 A) of these beads as reported by the
manufacturer, but this could be due to steric hinderance, and may be improved by extending
Jagged1 incubation time up to 120 mins as given by the Protein G bead manufacturer guidelines
and as done in some protocols9,32,33. Figure 4-3 B shows the dose-dependent response of
HCASMCs by increasing Jagged1 pre-coat concentration, using RT-qPCR gene expression of
Acta2 and Cnn1. For the remaining experiments, 2.5 µg/ml Jagged1 was used as this concentration
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was sufficient to show an induced contractile SMC expression and optimizes loss of protein in the
wash fraction.

Figure 4-3 Jagged1 immobilization to Protein G beads in a concentration-dependent manner.
Recombinant Jagged1 was immobilized to Protein G magnetic DynabeadsTM through absorption
for 10 mins on rotation at room temperature. A) Wash fractions were obtained and quantified by
an ELISA assay then subtracted from the total protein immobilized to quantify total protein
immobilized to the bead fraction B). Immobilized Jagged1 beads with 0-5 µg pre-coat were culture
with HCASMCs and gene expression levels of Acta2 and Cnn1 were investigated using RT-qPCR.
* indicates significance from the control p<0.05.

4.1.1.4. Immobilized Jagged1 directs protein levels of HCASMCs
The effect of immobilized Jagged1 driven SMC response was also translated to the protein
level evaluated both by Western blot (Fig. 4-4) and immunofluorescence microscopy (Fig. 4-5).
Both immunofluorescence microscopy and Western blot analysis demonstrated that soluble
Jagged1 had no effect on the SMC contractile genes. Additionally, soluble Jagged1 did not
influence Jagged1 ligand or Notch3 receptor protein levels (Figure 4-4 B, C).
Similar to the gene expression data for immobilized Jagged1, protein analysis also
demonstrated a positive role of immobilized Jagged1.The upregulation of Acta2 was shown using
Western Blot (Figure 4-4 D), demonstrating a 3-fold increase in relative band intensity, and
immunofluorescent imaging (Figure 4-5 D) of Acta2 revealed a 2.5-fold increase in relative
fluorescence intensity when normalized to the control. Furthermore, Cnn1 (Fig. 4-4 E) showed an
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upregulation, in line with the gene expression data presented previously. Lastly, an unchanged
Myh11 immunofluorescence expression indicated that Jagged1 beads did not have an observable
effect (Fig. 4-5 F). Collectively, these data strongly indicate the influence of immobilized Jagged1
on early-stage contractile protein markers was more considerable than the late-stage markers.

Figure 4-4 Western blot analysis of Notch induced contractile proteins Jagged1 and Notch3
protein levels.
Jagged1 driven SMC contractile marker protein expression was analyzed using Western Blot
analysis. Representative blots are shown in A). Western Blot band intensities of B)Jagged1,
C)Notch3, D)Acta2, and E)Cnn1 were quantified using ImageJ. Band intensities were normalized
to GAPDH and plotted as the normalized expression of the untreated culture. Three independent
band readings were taken, and the * indicates significance (p<0.05).
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Figure 4-5 Contractile marker protein expression of HCASMC’s with the treatment of
soluble and immobilized Jagged1.
Immunofluorescence staining of HCASMCs comparing soluble and immobilized delivery of
Jagged1 were used to determine the expression of contractile protein markers upon Notch
activation. Cells were stained with A1) early-stage contractile marker Acta2 and B1) late-stage
contractile marker Myh11. In all panels moving horizontally to the right show DAPI staining
(blue), F-Actin staining (green), the protein of interest (red) and merged images. Scale bar: 50 µm.
HCASMCS cultured alone were used as a control. Quantification (using ImageJ) of the relative
fluorescence quantification of Acta2 expression A2, A3), and Myh11 expression B2, B3) are
shown to the right. Data are presented as the mean fluorescence from multiple readings ± SD
normalized to the control HCASMCs cultured alone in SmGM. * indicates statistical significance
in comparison to the control group at p<0.05.
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The representative Western blots also demonstrate the influence of Jagged1 immobilization
on relative ligand-receptor (Jagged1-Notch3) expression levels in HCASMCs (Fig. 4-4 B,C).
These results suggest that immobilized Jagged1 also had control of the relative ligand-receptor
expression levels. Ligand and receptor levels are important because Notch is driven by
stochiometric interactions compared to other signaling pathways which are enzymatically driven.
Thus, the Notch target gene expression is reported to increase in a dose-dependent manner34–36.
Bead-bound Jagged1 delivery were able to enhance the expression of Notch3 expression and
subsequently Jagged1 expression in the signal-receiving cell shown by the Western blot
(quantified in Fig 4-4 B). The induction of Jagged1 expression in the differentiated SMCs is critical
to support a simple feed-forward pathway by sequentially activating differentiation and
maintaining homeostasis in the subsequent SMC layers, a process known as lateral induction37.

4.1.2.
The effect of Notch inhibitor on HES1 and contractile marker
expressions
Since evidence has shown and demonstrated a critical role of Notch signaling in both vascular
remodeling as well as pathogenesis and disease in cardiovascular health, both activation and
inhibition of Notch signaling can be important for designing treatments. The use of gammasecretase inhibitors, including DAPT have been shown to inhibit or attenuate the Notch signaling
pathway in literature 20,39–41. To directly implicate Notch to SMC contractile phenotype, a Notchspecific gamma-secretase inhibitor DAPT was used to attenuate Jagged1-induced Notch signaling
shown in Figure 4-6. Mechanistically, DAPT blocks the Notch intracellular domain (NICD)
cleavage at the S3 domain, which prevents subsequent translocation of Notch3 to the nucleus (Fig.
4-6 A). DAPT treatment of HCASMC attenuated both the Notch transcription factor HES1 and
contractile protein markers Acta2 and Cnn1 (Fig. 4-6 B-D). However, there was no significant
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effect on Myh11 (Fig. 4-6 E); therefore, Notch may not be directly responsible for Myh11
expression levels and may rely on the interaction with other signaling pathways.
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Figure 4-6 Smooth muscle cell phenotype was directly affected by activating Notch signaling,
demonstrated by a specific Notch inhibitor DAPT.
HCASMCs were cultured on a 24 well plate for 2 days. On day 2, cells in the DAPT group were
treated overnight with 10 µM DAPT. On day 3, SMC media was exchanged and then cells were
incubated for 3 days with i) immobilized Jagged1/Fc beads or ii) DAPT (10µM) and Jagged1-Fc
immobilized beads. DAPT, a specific S3 inhibitor, preventing cleavage of the NICD A).
Expression levels of B) HES1, C) Acta2, D) Cnn1, and E) Myh11 were quantified by RT-qPCR
and normalized to the untreated HCASMC culture control. Significant downregulation by DAPT
inhibitor suggests a clear link between Notch signaling and these target proteins, demonstrating
Notch signaling cause and effect in HCASMCs. Treatment groups were normalized to the SMC
control set to a value of 1 (not shown) and represented as the normalized fold change. * indicate
statistical significance in comparison to the control group at p<0.05.
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4.1.3.
Serum starvation of HCASMC for enhanced contractile protein
expression
It was surprising that HCASMCs did not express mature contractile markers, including
myosin heavy chain in the previous experiments. Myosin heavy chain is a hallmark contractile
protein for mature smooth muscle cells. In culture HCASMCs generally undergo a phenotype
switch and acquire a more synthetic phenotype. To test the capability of these cells to undergo
phenotype transition and express mature markers (which was not seen with immobilized Jagged1),
other factors and culture conditions were investigated to drive this transition. Serum deprivation
is a known culture condition to induce a phenotypic change of vascular smooth muscle cells with
an elongated/spindle-shaped morphology, an elevated myofilament density, and reacquired
contraction38. Therefore, this was used to induce functional protein expression and a contractile
morphology. To analyze this response and stimulate late-stage contractile markers, HCASMCs
grown to sub-confluence were serum-starved for 72 hours and imaged using immunofluorescent
microscopy (Fig. 4-7). The addition of 2ng/mL TGFβ1 was also used as an additional factor to
induce further functional protein expression and phenotype switching.
Serum starvation successfully caused morphological changes in the HCASMCs. Cells were
morphologically elongated and spindle-shaped upon serum starvation which is indicative of a
mature contractile SMC. Serum starvation of HCASMCs was also able to significantly stimulate
the expression of Calponin1/2/3, similar to expression levels as seen with immobilized Jagged1
(Fig. 4-7 A). Expression of myosin heavy chain and smoothelin were induced with these treatment
conditions which were lacking upon Jagged1 treatment (Fig. 4-7 B,C). This increase was also
enhanced upon treatment with TGFβ1 in the culture media. Therefore, serum starvation, in
combination with TGFβ1 enhanced transition into a mature contractile phenotype. This also
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suggests that bead-bound Jagged1 alone may not be an optimal culture system to induce a fully
mature contractile SMC.
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Figure 4-7 Serum starved HCASMC protein expression and morphological changes
HCASMCs were cultured for 72 hours in serum-free-DMEM, with and without 2ng/mL TGFβ1
to further induce contractibility. HCASMCS cultured alone in SmGM were used as a control.
Immunofluorescent staining of A) Cnn1/2/3, B) Myh11 and C) Smtn is shown. Scale bar: 20 µm.

4.1.4.

Jagged1 signaling cross-talk with TGFb1 in HCASMC
Many developmental processes that are regulated by Notch signaling are also controlled

by TGFβ family of ligands, including BMP and TGFβ. As discussed in Section 2.7.1, Notch
signaling has been identified to play a role in the vasculature and ligands such as TGFb1 have been
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identified for providing a specific role in SMC phenotype control2, ECM synthesis, VSMC
proliferation and VSMC migration42. The influence of both Jagged1 and TGFb1 on the expression
of smooth muscle cell markers are presented in Figure 4-8.
The data demonstrated that both Jagged1 and TGFb1 direct SMC regulation by significant
upregulation of HES1 a Notch transcription factor as well as contractile protein markers Acta2 and
Cnn1. Jagged1 signaling influenced the expression of HES1 more drastically as there was an 8fold increase compared with 3.5-fold increase with TGFb1 (Figure 4-8 A). It is interesting that
TGFb1 also influenced HES1 which is not a direct target, but this upregulation of HES1 is
consistent with other reports in literature43. TGFb1 is a more prominent effector on SMC response,
especially with late-stage contractile genes (Figure 4-8 B,C). Using TGFb1 treatment alone, it
was possible to significantly upregulate Myh11 expression which was not achieved with Jagged1
Notch treatment. A limitation of this study was that the relative concentration dependence was not
investigated and is an avenue for future research.
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Figure 4-8 Comparison of Jagged1 and TGFb1 ligands to direct HCASMC phenotype
control.
HCASMCs were cultured for 3 days in a 24-well plate with the addition of i) immobilized
Jagged1/Fc beads (2.5µg/mL) or ii) 2ng/mL soluble TGFb1. Expression levels of A) HES1, B)
Acta2, C) Cnn1, and D) Myh11 were quantified by RT-qPCR and normalized to the untreated
HCASMC culture control. Significant upregulation of all genes was observed with both TGFb1
treatment. Jagged1 signaling in comparison only upregulated HES1, Acta2 and Cnn1. Both of these
pathways thus play a direct role in SMC control and differentiation. Data is presented as the mean
± SD normalized to the control HCASMCs cultured alone in SmGM, and the symbols (*, #)
indicate significance from each other p <0.05.
Since Jagged1 and TGFb1 ligands both contribute to vascular development and
pathogenesis44–47, the integration of these two pathways could be useful29. The ability for Notch
signaling

components

to

interact,

impact,

and

cross-talk

with

multiple

signaling
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pathways/components adds complexity to controlling Notch signaling. Although the current
understanding of the molecular mechanisms involved in Notch cross-talk is still in development,
there is evidence that several pathways are interconnected. The integration of multiple pathways
within the body is suggested to play a role in the abundance of Notch ligands and receptors before
receptor binding, and there is convergence within pathways in the body (discussed in Table 2-4,
Section 2.7.1). Notch and TGFb signaling have been identified as co-regulators of Smad proteins
indicating cross-talk between these pathways48,49,50. In Section 2.7.1 a discussion was provided
about the direct protein interaction within the two signaling pathways where the NICD
cooperatively interactions with Smad2/32, an intracellular transducer of the TGFb signaling
pathway.
In this study, the role of bead-bound Jagged1 and TGFb1 was investigated in combination.
In these experiments, HCASMCS were cultured for 3 days with immobilized Jagged1 beads
(2.5µg/mL, 200 beads/cell), soluble TGFb1(2ng/mL), or combination treatment. Results shown in
Figure 4-9 A indicated that both Jagged1 and TGFb1 directly upregulate HES1 gene expression
significantly compared to the controls in which HCASMCs were cultured in SmGM. In the
combination treatment, HES1 expression is also slightly increased compared with Jagged1 or
TGFb1 treatment group. Therefore, there is an added effect of Notch activation by using a
combination of the two ligands. When analyzing the effect of Jagged1 and TGFb1 treatment on
smooth muscle cell contractile genes, both treatment groups significantly upregulated SMC
contractile genes Acta2, and Cnn1 as shown in Figure 4-9 B,C. Again, the combination treatment
significantly upregulated these contractile markers further. Lastly, TGFb1 treatment significantly
upregulated Myh11 expression which then was increased slightly by the combination treatment of
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Jagged1 and TGFb1 (Figure 4-9 D). It is interesting to note that alone Jagged1 has no effect on
Myh11 expression but provided added therapeutic benefit in combination with another signaling
ligand.
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Figure 4-9 Investigating the synergistic relationship between TGFb1 and Jagged1 ligands.
HCASMCs were cultured for 3 days with immobilized Jagged1 beads (2.5µg/mL, 200 beads/cell),
soluble TGFb1 (2ng/mL) or a combination treatment. DAPT, a Notch specific inhibitor, was also
added in combination to demonstrate Notch-specific response of both ligands. Gene expression
levels of human HES1 (A), Acta2 (B), Cnn1 (C), and Myh11 (D) are shown. The symbols indicate
statistically significant. Data are presented as the mean ± SD normalized to the control HCASMCs
cultured alone in SmGM. Symbols indicate significance compared to the control p <0.05. Control
refers to HCASMCs cultured in SmGM
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Cross-talk was further confirmed using a Notch inhibitor. DAPT inhibits the (S3) intracellular
domain cleavage of the Notch receptor. Since TGFb1 signaling is also attenuated by DAPT, there
may be a relationship between the NICD and TGFb intracellular components. DAPT specifically
attenuated signaling in both Jagged1 and TGFb1 treated cells for HES1, Acta2, and Cnn1. It is
important to note that Myh11 gene expression was not significantly attenuated by DAPT when
treated with TGFb1, suggesting mechanisms other than Notch signaling may be in play for this
gene. Since Jagged1 and TGFb1 concentrations were fixed, it is unknown if dosing has an effect.
The relative contribution of each ligand in the combination treatment was not studied.
In addition to RT-qPCR data, immunofluorescence and Western blotting were used to evaluate
protein levels. As shown in Figure 4-10 A-D, calponin which is one of the early-stage SMC
differentiation markers, was robustly expressed at the protein level by both TGFb1 and Jagged1.
Consistent with the RT-qPCR data, the Notch inhibitor attenuated calponin. Contrary to calponin,
the late-stage contractile marker smoothelin was not affected by either TGFb1 or Jagged1 (Figure
4-10 E). The autofluorescence of protein G beads can be seen in the red channel and was
discounted. Although a fully matured HCASMC is known to express smoothelin, the absence of
this marker suggested the lack of maturity – a hallmark for the synthetic phenotype. Longer
duration in a Jagged1 activated state might also be required to show significant smoothelin
expression.
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Figure 4-10 Effect of Jagged1 and TGFb1 on protein expression in HCASMCS to control
smooth muscle cell markers analyzed by immunofluorescence imaging
HCASMCs were cultured for 2 days, and then incubated for an additional 3 days with the following
treatments i) Jagged1-Fc (2.5µg/mL) immobilized beads (200 beads/cell), ii) Jagged1-Fc
immobilized beads (2.5µg/mL) + DAPT (10µM), and iii) TGb1 (2ng/mL). Protein level was
confirmed by immunofluorescence staining. Calponin (Cnn1) (A) and smoothelin (E). The bar
graphs are the corresponding quantification of the images; (B-D) for calponin and (F-G) for
smoothelin. Scale bar= 50"m. Both Jagged1 and TGFb1 significantly showed increased
expression of Cnn1 but not Smtn. Data is presented as the mean fluorescence intensity from
multiple readings ± SD normalized to the untreated control HCASMC. * indicates statistical
significance in comparison to the control group at p<0.05.
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Figure 4-11 Effect of Jagged1 and TGFb1 on protein expression in HCASMC to control
smooth muscle cell markers analyzed by Western blot
HCASMCs were cultured for 2 days, and then incubated for an additional 3 days with the following
treatments i) Jagged1-Fc (2.5µg/mL) immobilized beads (200 beads/cell), ii) Jagged1-Fc
immobilized beads (2.5µg/mL) + DAPT (10mM), and iii) TGb1 (2ng/mL). Protein expression was
confirmed by Western Blot analysis, and representative blots of the experiment are shown in A).
Band intensities were normalized to GAPDH and plotted as the normalized expression of the
untreated control culture. HCASMCs cultured in SmGM served as controls. The relative band
intensities for Jagged1 and DAPT treated cells are quantified in B1-B4. The relative band
intensities for Jagged1 vs. TGFb1 ligand presentation were quantified in C1-C4. Data are
represented as mean band reading ± SD. The symbols (*,#) indicate statistically significant
differences from each other (p<0.05).
Western blot was also used to confirm the gene expression data (Fig 4-11 A). An upregulation
of Notch3 (~16-fold), Jagged1 (~6-fold), Acta2 (~3 fold), and Cnn1 (~ 7-fold) was observed and
was attenuated by DAPT treatment. The data also showed that both Jagged1 and TGFb1 are able
to upregulate the expression of both Acta2 and Cnn1 protein expression. To summarize the role of
Jagged1 on HCASMC, immobilization was a necessary, perhaps not a sufficient condition for
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enhancing phenotype modulation and revealed evidence for cross-talk between Notch and TGFb
intracellular components.

4.2. Effects of Jagged1 delivery for vascular smooth muscle cell differentiation
of stem and progenitor cells
HCASMCs are a great model to investigate Jagged1-specific Notch activation and response.
Nevertheless, HCASMCs can only be used as a model cell since harvesting them from the coronary
arteries of patients is not feasible. Therefore, other model cells, and autologous cell sources need
to be explored. Cellular therapies often use allogenic or autologous sources for therapeutic
strategies; however, it is often difficult to maintain a homogenous and convenient cell source to
generate cells with a stable phenotype and function. In this study iPSC-MSCs and 10T1/2 cells
were investigated for their Jagged1-specific differentiation.

4.2.1.

The effect of Jagged1 on iPSC-MSC differentiation towards VSMC

Rather than using primary cell sources, an alternative cell source for vascular tissue
engineering is induced pluripotent stem cells (iPSC)51. iPSC-MSCs can be derived from human
skin fibroblast cells and can become reprogrammed by viral overexpression of specific
transcription factors. Retroviral transduction of Oct4, Sox2, Klf4, and c-myc is a common
approach52,53. These iPSCs can then be differentiated into an MSC lineage and further matured
into a smooth muscle cell. This process is summarized in Figure 4-12.
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Figure 4-12 Generation of patient specific iPSCs from fibroblast cell reprogramming and
subsequent differentiation to a smooth muscle cell lineage.
Notch signaling has been a target for iPSC-MSC cell fate decisions into cardiac and neuronal
differentiation. For example, ascorbic acid for mesoderm induction, followed by DAPT (Notch
inhibition) accelerated the generation of beating cardiomyocytes54. Compared to bone marrowderived MSCs, vascular differentiation of iPSC-MSCs were less responsive to traditional
differentiation protocols and thus proved to be difficult55. Since Notch signaling is critical in
development and specifically cell fate determinations, including progenitor differentiation, it is
beneficial to determine if Notch signaling could be harnessed for mature contractile SMC
differentiation. The induction of smooth muscle gene expression in mesenchymal stem cells has
been effective in activating Notch signaling as demonstrated by HES1 upregulation, and increased
Myh expression56. Therefore, the aim here was to determine if Jagged1 could direct iPSC-MSC
differentiation into a smooth muscle cell lineage.
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Figure 4-13 Differentiation of iPSC derived MSCs by Jagged1
iPSC derived mesenchymal stem cells were cultured for 4 days followed by the addition of soluble
Jagged1, protein G beads or Jagged1 immobilized beads for an additional 3-day culture. RT-qPCR
analysis revealed that soluble Jagged1 has no effect, but immobilized Jagged1 significantly
upregulates A) HES1 transcriptional factor and smooth muscle cell (SMC) contractile marker
genes (B) Acta2, C) Cnn1 and D) Myh11). The bead concentration was 200 beads/cell and 2.5 µg
of Jagged1 protein was immobilized or added as a soluble protein. Data are represented as mean
± SD normalized to the control HCASMCs cultured alone in SmGM. * indicates significance at p
< 0.05.
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As was seen previously for HCASMCs, iPSC-MSCs were also responsive to Jagged1(Figure
4-13). While soluble Jagged1 did not influence differentiation, immobilized Jagged1 was able to
differentiate iPSC-MSCs into a SMC lineage. Both an upregulation of the Notch transcription
factor HES1 and contractile protein markers smooth muscle Acta2 and Cnn1 and Myh11. This was
linked directly to the Notch signaling pathway because DAPT was able to attenuate iPSC-MSC
differentiation.
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Figure 4-14 Vascular differentiation of iPSC-MSC using immobilized Jagged1
iPSC-derived mesenchymal stem cells were cultured for 4 days, then of Jagged1 immobilized
beads was added for an additional 3-day culture. The addition of 10 µM DAPT pre-treatment
overnight followed by a combination of 2.5µg/mL Jagged1 + 10 µM DAPT. Expression of A)
HES1 B) Acta2, and C) Cnn1. Data are presented as the mean ± SD normalized to iPSC-MSC’s
cultured alone in SmGM (not shown). * indicates significance compared to Jagged1 treated iPSCMSCs, p <0.05.
Similar effects were seen using Western blot analysis (Figure 4-15). These data suggested that
undifferentiated iPSC cells could be driven towards a SMC lineage and could be useful for vascular
tissue engineering. Quantification of the representative blots shown in Figure 4.15 indicates the
increased expression of HES1 but not Myh11 at the protein level. These cells showed a similar
response to HCASMCs. Jagged1 beads also increased the expression of Acta2 and Cnn1. DAPT
was able to attenuate the Jagged1 expression, supporting the previous observation. In conclusion,
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immobilized Jagged1 could be useful in directing the differentiation of iPSC-MSC towards a
smooth muscle cell lineage. These cells still lack the expression of more mature contractile
markers, including Myh11. It is suspected that other biochemical factors, along with Jagged1 may
be required to fully mature these cells.
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Figure 4-15 Smooth muscle protein expression of iPSC-MSCs driven by Jagged1 signaling
iPSC derived mesenchymal stem cells were cultured for 4 days and then treated with Jagged1
beads (200 beads/cell and 2.5µg/mL of Jagged1). Western Blot analysis was done to confirm
protein expression. Representative blots are shown in A). The relative band intensity for B) HES1,
and C) Myh11. iPSC-MSCs cultured alone served as controls. To confirm a Notch specific
differentiation, representative blots are shown in D). Relative band intensity of both E) Acta2 and
F) Cnn1 were quantified. Data are represented as mean blot intensity ± SD. Treatment groups were
normalized to the iPSC-MSC controls grown in SmGM and represented as the normalized fold
change. The symbols (*,#) indicate statistically significant differences from each other (p<0.05).
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4.2.2.

Vascular differentiation of 10T1/2 cells using Jagged1

Extending the findings of HCASMC and iPSC-MSC, the use of bead-bound Jagged1 was
expanded to the mouse embryonic multipotent mesenchymal progenitor cell line (10T1/2 cells).
These cells have been used as a model for cartilage and bone tissue engineering and gained
attention in vascular tissue engineering57. The differentiation of 10T1/2 cells into a SMC lineage
has been demonstrated using a co-culture with endothelial cells or treatment with TGFb158,59. In
this thesis, the aim was to determine the influence of Jagged1 delivery by studying the effects of
TGFb1 and Jagged1 on 10T1/2 cells differentiation. In the first experiment the potential of these
cells to differentiate and express smooth muscle cell markers in response to 2ng/mL TGFb1 Figure
4-16 was observed.
Upon delivery of TGFb1, HES1, Notch3, and SMC markers Acta2 ,Cnn1,and Myh11 are
significantly upregulated. A similar protein expression of Acta2, Smtn and Myh11 to that of
HCASMCs was seen with the treatment of TGFb1 which has been recently published58. This
differentiation approach using TGFb1 is attractive; however, research has shown that TGFb1
failed to fully differentiate these into SMCs due to inconsistent expressions of myocardin,
smoothelin, and myosin-heavy chain60–62.
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Figure 4-16 Differentiation of embryonic multipotent mesenchymal progenitor cell (10T1/2
cells) into a smooth muscle cell lineage using TGFb1
10T1/2 cells were cultured for 3 days in DMEM with 2ng/mL TGF#1. RT-qPCR analysis of A)
HES1, B) Notch3 and contractile SMC markers, C) Acta2, D) Cnn1 and E) Myh11 were used to
show differentiation of 10T1/2 cells into a SMC lineage. Upregulation of all three markers
demonstrates a commitment to a SMC lineage. * indicates significance from the undifferentiated
control represented as a normalized mean ± SD (p < 0.05).
Since Notch signaling has been successful in controlling phenotype switching of HCASMC,
and vascular differentiation of iPSC-MSCs, 10T1/2 cell differentiation induced by Jagged1 was
explored. Soluble ligands can bind to Notch receptors but are, for the most part, unable to activate
signaling. Instead, they appear to block signaling induced by trans-ligands in most cases63.
Although more commonly soluble Notch ligands have been applied to cell-based systems to
competitively inhibit Notch signaling, activation through soluble Notch signaling has been highly
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debated and seems to be highly context-dependent, as discussed in Section 2.6.1. In primary cells
only cochlear24 and human foreskin keratinocytes22 are reported to be responsive to soluble
Jagged1 to promote differentiation, supporting context dependency. Soluble Jagged1 was
especially useful in differentiating MSCs into cardiomyocytes21, peripheral blood mononuclear
cells into monocytes64, and differentiation of dendric cells23. This suggests the potential for soluble
Jagged1 to be effective in stem cell and progenitor cell differentiation. Thus, the effect of soluble
Jagged1 delivery on 10T1/2 cell response was studied. As shown in Figure 4-17, neither
undifferentiated nor pre-differentiated 10T1/2 cells were responsive to s-Jagged1. Notch activation
monitored by HES1 was not significantly changed, and cells did not express increased smooth
muscle cell markers Acta2 and Cnn1.
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Figure 4-17 The effect of soluble Jagged1 delivery on multipotent 10T1/2 cells
10T1/2 cells were cultured for 3 days in DMEM with or without 2ng/mL TGF#1. Both predifferentiated and undifferentiated 10T1/2 cells were treated with soluble Jagged1 at a
concentration of 2.5µg/mL for an additional 3 days. RT-qPCR analysis of HES1, Acta2, and Cnn1
were used to show Notch specific differentiation of 10T1/2 cells. No response to s-Jagged1
indicates soluble Jagged1 was insufficient to differentiate 10T1/2 cells into a SMC lineage. The
data is represented as a normalized mean ± SD. * indicates significance from the pre-differentiated
or undifferentiated control, respectively at p < 0.05.
Previously, Jagged1-selective Notch signaling has been linked to smooth muscle cell
differentiation via a RBP-Jk-dependent pathway in 10T1/2 cells by forced Notch1-NICD
expression65. Therefore, the influence of immobilized Jagged1 on 10T1/2 Notch3-directed SMC
vascular differentiation was analyzed. Undifferentiated and pre-differentiated 10T1/2 cells were
treated with Jagged1 immobilized beads according to the protocol shown in Figure 4-18 A.
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Figure 4-18 Response of pre-differentiated and undifferentiated 10T1/2 cells by Jagged1
directed Notch signaling.
10T1/2 undifferentiated and pre-differentiated (2ng/mL TGF#1 for 3 days) were cultured for 3
days in the presence of Jagged1 immobilized beads (200 beads/cell and 2.5µg) (A). RT-qPCR
analysis of B) HES1, and C) Notch3 as well as contractile SMC markers D) Acta2, E) Cnn1, and
F) Myh11 were used to show vascular differentiation. The addition of Jagged1 to undifferentiated
and pre-differentiated 10T1/2 cells show that pre-differentiation improved Notch response in
10T1/2 cells. Only the upregulation of HES1 and Notch3 in undifferentiated 10T1/2 cells
demonstrate a Jagged1 Notch response. The symbols indicate significance with respect to the
control represented as a normalized mean ± SD (p < 0.05).
Although undifferentiated 10T1/2 cell expression of HES1 and Notch3 were responsive to
immobilized Jagged1 beads, SMC contractile protein expression was not significantly upregulated
(Figure 4-18 D-F). 10T1/2 cells were more responsive to Jagged1 after pre-differentiation with
2ng/mL of TGFb1. Upon pre-differentiation, a significant fold increase of HES1, Notch3, and all
evaluated SMC genes were responsive to the addition of 2.5µg of Jagged1. This implies that
10T1/2 cells may need a partial commitment to a SMC lineage for Jagged1 directed Notch
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signaling has a strong influence on cell response. Without pre-differentiation of these cells, it is
possible that Jagged1 might direct differentiation to other cell lineages which may be a possible
avenue to explore further. To ensure the Notch specific response of these genes, DAPT inhibition
was used (Figure 4-19). Pretreatment of differentiated 10T1/2 cells with 10µM DAPT was used
to inhibit S3 cleavage when treated in conjunction with Jagged1 immobilized beads, shown in
Figure 4-19 A. All genes except for myosin heavy chain were responsive to Notch inhibition,
indicating a link between regulation of these genes and Notch activation.
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Figure 4-19 Notch specific differentiation of 10T1/2 cells
Pre-differentiated 10T1/2 (treated with 2ng/mL TGF#1 for 3 days), were pretreated with 10 mM
DAPT overnight then cultured for 3 days in the presence of Jagged1 immobilized beads (200
beads/cell and 2.5µg/mL). The scheme shown in A) Cell response was compared to Jagged1
treated cells alone and normalized to 10T1/2 cells cultured alone. Pre-differentiated 10T1/2 cells
treated with Jagged1 with DAPT showed significant downregulation of target genes B) HES1,
C)Acta2, and D)Cnn1. * indicates significance from Jagged1 treated 10T1/2 cells, and data are
represented as a mean ± SD and normalized to the pre-differentiated control (p < 0.05).
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Protein expression was used to confirm that these cells are being directed towards a SMC
lineage. SM $-actin was observed in both immunofluorescence imaging and Western blot (Figs.
4.20 and 4.21). Although this data is promising, Jagged1 treatment was insufficient to show a clear
increased expression of smoothelin immunofluorescent staining (not detectable), which would
confirm and SMC phenotype. SM $-actin is a SMC marker but is also found expressed in other
cell types; thus, it is unclear if there is a mixed cell population. Therefore, further work would be
needed to explore other methods to promote a fully differentiated SMC phenotype.
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Figure 4-20. Immunofluorescence microscopy of undifferentiated and pre-differentiated
10T1/2 cells treated with Jagged1
Undifferentiated or pre-differentiated (treated with 2ng/mL TGF#1 for 3 days) 10T1/2 cells were
plated on glass cover slides at a density of 30 000 cells/ slide, and then treated with Jagged1 beads
(200 beads/cell and 2.5µg/mL) or Jagged1 beads + DAPT (10mM). F-actin (red), nuclei (blue) and
Acta2 (green). The corresponding quantification of the images. Scale bar = 50"m.
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Figure 4-21 Western Blot protein analysis of undifferentiated and pre-differentiated 10T1/2
cells treated with Jagged1
Undifferentiated or pre-differentiated (treated with 2ng/mL TGF#1 for 3 days) 10T1/2 cells were
plated and then treated with Jagged1 beads (200 beads/cell and 2.5µg/mL) or Jagged1 beads +
DAPT (10mM). Jagged1 beads upregulated Acta2 protein in differentiated 10T1/2 cells. Western
blots are shown in A). The relative band intensity is quantified in the bar diagrams on the right and
were normalized to the GAPDH control B), and relative expression expressed as a fold increase
compared to the undifferentiated control. Data is represented as a mean ± SD. (p < 0.05)
Taken together, although the influence of immobilized Jagged1 delivery on the differentiation
of these cell types into a smooth muscle cell lineage was insightful, other biochemical (e.g.,
ascorbic acid) or topographical (e.g., 3D scaffolds) need to be investigated to achieve a fully
mature SMC for vascular tissue engineering.

4.3. Molecular mechanotransduction and Notch3 signaling
The final objective in this thesis was to explore Notch mechanotransduction to potentially
enhance signaling efficacy because Notch signaling has been shown to be a mechanosensitive
pathway66,67. The concept of a pulling force requirement for Notch activation has been around for
nearly two decades; however, only recently have studies used molecular force measurements to
prove this hypothesis. As discussed in Section 2.7.2, a tension force delivered to the receptorligand complex permits a conformational protein unfolding, which allows the active site for
ADAM cleavage (S2) to be available. This conformation change is then able to activate
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downstream targets of the Notch pathway. There are also conflicting reports about the
responsibility of receptor clustering and oligomerization and their force contribution to Notch
activation66,68,69.
Mechanical loading has appeared to be sufficient to activate the receptor in absence of the
native cell-bound ligand70. Force-dependent shedding of the NECD was also confirmed by
utilizing 1:1 (bead:receptor) binding of magnetic nanoparticles to activate single Notch receptors.
Therefore, it is believed that a mechanical force, in addition to ligand-receptor binding, is needed
for Notch activation and demonstrated with DLL111,71, and DLL4
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ligands. Since there are

structural differences between Notch ligands, it is not known if mechanical loading of Jagged1 is
needed to activate Notch signaling in SMCs. It is postulated that additional biochemical or
structural cues that are not offered by the Jagged1-immobilized beads may be necessary to activate
the signaling cascade that results in SMC Notch activation, but this is unknown. In view of the
above discussion, the next objective is to evaluate whether or not the Jagged1-Notch3 pairing is
mechanosensitive.

4.3.1.
The effect of tension force for Notch3 activation and phenotype
control of smooth muscle cells
Jagged1-conjugated magnetic nanoparticles were used as a tool to study how applying tension
to cells can change the activation of Notch signaling using a magnetic tweezer setup. The magnetic
tweezer set up was selected when compared to other force application techniques because the
versatility of attachment to the beads, low heat/photodamage as seen with optical tweezers, the
ability to achieve a constant force, and the ability of the tweezer setup to apply large force ranges.
Although this platform is limited because of the magnetic variability in the bead population, the
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low resolution if using a video-based bead detection system, and lack of knowledge on eliminating
the torque on the beads, this system was acceptable for the present study (Figure 4-22).

Figure 4-22 Mechanosensitivity of HCASMC to Jagged1 under tension
HCASMC were cultured in a 96-well plate for 2 days to allow for cell spreading and attachment,
then treated with Jagged1-immobilized beads. Cells were cultured for another 2 days under the
application of a magnetic tension force. Expression levels of HES1, Acta2, and Cnn1 were
quantified with RT-qPCR and normalized to the control cultures without the magnetic plate. The
bead concentration was 200 beads/cell and 2.5µg/mL of Jagged1 protein was immobilized to that
bead concentration. Data are represented as mean ± SD. * represents significance at p < 0.05.
When cells expressing the Notch3 receptor were incubated with Jagged1-immobilized
magnetic nanoparticles, there was a significant increase in contractile gene expression upon
addition of the Jagged1 beads demonstrating that our system works in a 96-well plate format. Upon
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application of a magnetic tension force to HCASMCs there was no significant cellular response,
demonstrating that the force magnitude or the magnetic beads alone are not affecting the signal.
Upon treatment with Jagged1 beads and a magnetic tension force, a significant downregulation of
HES1 and Acta2 but not Cnn1 was observed in comparison to the Jagged1 treated cells with no
magnet. These results were confirmed in 10T1/2 cells. Pre-differentiated 10T1/2 cells were used
because they were proven earlier to be more responsive to Jagged1. Similar to what was seen in
the HCASMCs, the addition of a magnetic plate to Jagged1 treated cells downregulated HES1 and
Acta2 gene expression (Figure 4-23). The magnetic tension force had no effect on the cells
cultured without beads.

Figure 4-23 Mechanosensitivity of 10T1/2 cells to Jagged1 under tension
Pre-differentiated 10T1/2 cells were cultured in a 96-well plate for 2 days to allow for cell
spreading and attachment, then treated with Jagged1-immobilized beads. Cells were cultured for
another 2 days under the application of a magnetic tension force. Expression levels of HES1, Acta2,
and Cnn1 were quantified with RT-qPCR and normalized to the control of pre-differentiated
10T1/2 cells cultured alone with no magnetic plate. The bead concentration was 200 beads/cell
and 2.5µg/mL of Jagged1 protein was immobilized to that bead concentration. Data are represented
as mean ± SD. * represents significance at p < 0.05.
By controlling the distance between the cells and the magnet, it is possible to vary the force
applied to the cells as a function of the height from the PDMS surface to the plate lid. To present
cells at various heights, PDMS polymer was dispensed into the culture chamber, creating a
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“terraced” configuration with wells of different depths across the plate.70 Various heights were
tested by adding different PDMS, including the addition of the reported 100µL corresponding to
~2pN force. As shown for both HCASMC and 10T1/2 cells, increasing the height did not
significantly affect HES1 gene expression and further downregulated Acta2 (Figure 4-24 A, B).
Similar results were found for other heights with PDMS volumes ranging from 0-150µL (~ 0.5-5
pN), (data not shown). Suggested by this data, and contrary to previous reports that force
application would improve signaling efficacy72, the application of a magnetic tension force as a
function of height downregulated expression of HES1 and contractile marker Acta2. It appears that
the mechanosensitivity of Notch ligand-receptor pairing is context-dependent, similar to the
varying responses that are seen with activation or inhibition of the various ligand-receptor
combinations. Although Delta-like ligands have been shown to benefit from a molecular force,
this may not be the case with the Jagged1, specifically the Jagged1-Notch3 pairing in the SMC. It
suggests that the bead-bound Jagged1 provides enough traction force for Notch activation.
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Figure 4-24 Height and sensitivity on smooth muscle cell response
To create a terraced configuration of the 96-well plate, 100µL of PDMS was dispersed into the
well to increase the force magnitude applied to the cells. Force magnitude is a function of PDMS
height. The PDMS surface was then sterilized and treated with fibronectin. HCASMC or
differentiated 10T1/2 cells were plated on the two different well heights in the 96 well plate for 2
days to allow for cell spreading and attachment, then treated with Jagged1-immobilized beads.
Cells were cultured for another 2 days upon application of a magnetic tension force. Expression
levels of HES1 and Acta2 in both HCASMCs and pre-differentiated 10T1/2 cells were quantified
with RT-qPCR and normalized to the control of cells cultured alone with the addition of a magnet.
The bead concentration was 200 beads/cell and 2.5µg/mL of Jagged1 protein was immobilized to
that bead concentration. Data is represented as mean ± SD. Symbols indicate significance from
each other (p < 0.05).
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The finding that Jagged1-Notch3 pairing to be unresponsive to stretch forces provide insight
from a physiological perspective. In the native vasculature, endothelial cells are mechanosensitive
and are influenced by shear stress driven by blood flow in the vessel wall. The VSMCs in the
vascular wall experience strain due to the distention force and higher strain is found in thinner
vessels than in thicker vessels. The Jagged1-Notch pairing has been shown to be mechanosensitive
and influenced by strain and blood pressure in the vascular wall73,74. VSMCs to 10% uniaxial strain
demonstrated reduced expression of Notch3, Jagged1, HEY1, HEY2, and HES1, and decreased
further with increasing strain75. Furthermore, when looking at an array of receptors, ligands, and
transcription factors, Notch3 was the only receptor with a strain-responsive decrease in expression,
unlike Notch1 and Notch2. As for the ligands, Dll1 increased with increased strain, and Jagged1
decreased with increasing strain. HES1, HEY1, and HEY2 also decreased with increasing strain.
Together, this demonstrates that while Dll1 ligand is positively influenced by strain Jagged1 in
comparison is negatively affected, these cited studies, along with the present data, indicate that
Jagged1 may be negatively regulated by strain.
Additionally, vimentin networks have also been shown to effectively disperse locally induced
mechanical stress into larger regions enabling the dissipation throughout the cell76. Importantly
vimentin has also been linked as a requirement for efficient receptor-ligand transendocytosis77.
Vimentin has been reported as an important protein for Notch transactivation by ECs, and
proximity ligation assays have demonstrated direct vimentin interaction with Jagged177. Vimentin
knock-out mice showed disruption of VSMC differentiation and adverse remodeling75. Without
vimentin, there is a reduced structural component in the cytoskeleton, which may be responsible
for endocytosis and the pulling force to create NECD unfolding. However, Jagged1 beads were
able to rescue the maturation of SMCs in vimentin knock-out mice, which may indicate that no
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pulling force caused by trans endocytosis may be required for Notch activation. Therefore, and
similar to variable differentiation and cell response by transactivation Jagged1 vs delta-like
binding, there may be differences in the mechanosensitive nature of the ligands.
Lastly, as suggested earlier, clustering and oligomerization may also support the pulling force
for Notch activation. Thus, when Jagged1 is attached to Protein G beads via affinity
immobilization, the Jagged1-Fc fusion proteins may form pre clustered dimmers owing to the Fc
domain. While these clusters may not be capable of forming polymeric aggregates to generate
limited traction for the pulling force, it may be sufficient for Notch activation in SMCs, and thus
any additional strain to the surface would mimic increased blood flood in the vessel and negatively
affect Jagged1 signaling. More investigation is needed to elucidate this.
A schematic for translating the current approach into an automated magnetic tweezer set-up
is shown in Appendix A4. This design was inspired by other magnetic tweezers designs78–81, and
would be useful to achieve greater force ranges, improved accuracy, and improved visualization
of cell and bead behavior in real-time, which are all limitations of the current study.
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Chapter 5. Conclusions and Future Directions
5.1. Conclusions
Notch signaling has been identified as a promising target for many cellular therapies and
shows considerable progress and potential in directing and reprogramming cellular behavior.
Notch signaling can be utilized to engineer pre-vascularized thick tissues or to develop antiangiogenic cancer therapeutic strategies. Depending on the context, activating or suppressing
Notch signaling is a valuable tool to engineer tissues for therapeutic or diagnostic use. This, in
turn, allows creating diseased model tissues for studying drug discovery and screening. It has
already been demonstrated as a potential strategy to prevent atherosclerosis1, promote cardiac
valve regeneration2, reduce cell senescence in cell sheet engineering3, and to engineer vascular
tissues4,5. Specifically, Jagged1-Notch3 communication has been proven important in artery
homeostasis, and Jagged1 has been suggested as a promising target to maintain SMCs in a
contractile phenotype following injury. There has been considerable progress already made in the
development of Notch signaling biomaterials. While immobilized Jagged1 has been proven as a
promising biomolecule to control SMC response, an ongoing challenge is developing proper
biomaterial delivery platforms and obtaining mature expression of contractile proteins. This thesis
works towards enhancing our knowledge of Jagged1 delivery in SMC phenotype control and
differentiation in the vasculature.
The data in this thesis presented was able to regulate phenotype switching of HCASMCs using
bead-bound Jagged1, by inducing HES1 a Notch transcription factor, and early-stage contractile
markers, SM-actin, and calponin. To induce late-stage contractile marker co-delivery and cross
talk between Jagged1 and TGFb1 was necessary. To translate these findings to other vascular
smooth muscle cell sources, bead-bound Jagged1 was investigated to direct iPSC-MSC and 10T1/2
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cells towards a vascular lineage commitment. Although Jagged1 successfully directed the
commitment of these cells towards a SMC lineage, these cells lacked mature contractile markers,
including myosin heavy chain and smoothelin. Pre-differentiation of 10T1/2 cells was also needed
for increased Jagged1 response. Thus, it was concluded that Jagged1 should be studied in
combination with other factors to induce a fully differentiated phenotype. Lastly, this thesis
demonstrated that bead-bound Jagged1 did not require an additional tension force for Notch
activation which has been needed for Delta-like ligands.
Designing signal-presenting biomaterials for directed cellular therapies is a complex process
that requires precise control of signals. In conclusion, this research suggests promising therapeutic
potential for the Jagged1 ligand. In the long-term, these results could potentially be used for
Jagged1 stent technology to control vessel homeostasis until regeneration can occur following
stent deployments.

5.2. Future directions
Many researchers have largely focused on the cellular response-driven through a biochemical
perspective, but a major limitation in engineered tissues is driven from a biomaterial perspective.
Designing cell-instructive biomaterials incorporating the biological activity of proteins is an
emerging field. These biomaterials could be applied to the Notch signaling system to create a more
dynamic microenvironment and introduce tissue mechanics and activate mechanosensitive
receptors with various forces introduced. Since endocytosis of the ligand following receptor
binding generates the force to render Notch S2 cleavage, it implies that attaching the ligand to nondynamic surfaces may not be sufficient to activate Notch. Three strategies to address this could be
by use of supramolecular biomaterials/scaffolds that having dynamic, interchangeable, and
reversible motifs

6,7

, utilizing chemical spacers to provide more ligand-receptor dynamic
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interacted, or by reverse engineering of the Notch receptor for reduced pulling force dependency8.
Since the latter strategy involves transfection for synthetic Notch expression, supramolecular
materials or biomaterials incorporating biochemical spacers may be an attractive avenue from a
tissue engineering perspective. Regardless of the strategy to activate Notch signaling, it remains
to be an excellent tool for tissue engineering and regenerative medicine.
Future research would include dynamic interfaces at the biomaterial surface by introducing
chemical spacers. Research suggests that optimal ligand surface coverage can be maximized with
spacers due to the ability of the polymer-bound proteins to form a thick layer and dispersing the
ligands in space to optimize binding and minimize lateral repulsions9. Direct attachment of a
protein to a surface without a spacer can cause steric hindrance and reduced bioactivity of the
immobilized protein. In addition, without a spacer, multiple contacts between protein and
nanoparticle surface are more probable favoring total or partial protein denaturation and thus
decreasing protein activity10. There is some evidence for target selectivity of specific Notch
receptors by which the ability of Notch ICDs to form dimers might influence the activation of
downstream targets, including receptor recruiting of gene response11. Interestingly, the
configuration of CSL binding sites appearing as monomer or dimers have influenced the likelihood
of recruiting Notch1 or Notch3 ICD, respectively12. To mimic the dynamic regulation of signaling
ligands, polymer chemistry can be harnessed to create chemical spacers to improve biomolecular
recognition, ligand accessibility, and dynamic behavior of immobilization13.
Once the optimal strategy for presenting Jagged1 on a material surface is determined,
immobilization of Jagged1 in a 3D microenvironment or to stents would be the next step to
developing a functional treatment. As proposed, Notch functionalized vascular stents would be an
effective treatment to maintain vessel homeostasis and control SMCs until vessel regeneration can
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occur post angioplasty surgery. To test Jagged1-functionalized vascular stents, the response of
SMCs in a tissue-engineered vascular model to determine the effectiveness of this proposed
treatment is needed.
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Appendix A1: Advantages and disadvantages of current stent technology
Stent Type
a) Bare metal
stents

Composition

•
•
•
•

Stents
316L stainless steel
platinum-iridium alloy
tantalum, nitinol, cobaltchromium alloys
titanium

Advantages
•
•
•
•

b) Stent
coatings

c)

Drug
eluting
stents

d) Bioresorbable
stents

•
•
•

Stent +Coating
Gold, silicon-carbide
Iridium oxide
Diamond-like carbon

Stent + Coating + Drug
•
•
•
•
•

Paclitaxel,
Everolimus,
Sirolimus,
Myolimus
Novolimus

•

metallic (iron-based or
magnesium-based)
alloys
Polymers ex. PLLA and
PDLLA

•
•
•
•
•
•
•

•

•

Disadvantages

Maintains open artery
and reduces vessel
closure *
Provides structural
support *
Regains proper blood
flow *
Less invasive than bypass
grafts*

•
•
•
•
•
•

Metal scars endothelial tissue
Inert- no bioactivity
Prevents elastic recoil and
remodeling
Neointimal growth response
High rates of restenosis
Nondegradable

Reduced surface energy
Smoother surface
textures
Neutralized/stabilized
surfaces
Enhanced oxide layer
Reduces metal leaching
Drugs mitigate adverse
response to metal
Drugs target
immunorejection,
proliferation, and
antithrombosis
Reduces early restenosis*

•
•
•

No bioactivity
High rates of restenosis
Nondegradable

•
•

Incomplete healing
Includes chronic inflammatory
response
Increased risk of late stent
thrombosis
Need for antiplatelet therapy
Nondegradable

Expansive remodeling
possible
• Degradable
•
• No need for prolonged
double antiplatelet
therapy
• Restoration of
vasomotion
• Biocompatibility
e) Bioactive
• heparin1
• Potential recovery of
stents
biological function
• tripeptide Arg-Gly-Asp
2,3
• Controlled targeted
delivery
• vascular endothelial
growth factor (VEGF)
• Enhance rereendothelialization
• small interfering
ribonucleic acid
• Bioactivity
(siRNA) nanoplexes
•
Good biocompatibility
*indicates that this characteristic is common for all thereafter stent types

•
•
•
•

•

Not permanent-the artery must
regenerate at equal time of
stent degradation
Thicker and wider struts to
gain mechanical integrity
Larger catheter profile

•
•
•

Nondegradable
Late-stage stent thrombosis
In-stent restenosis

•

References: 4–9
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Appendix A2: Jagged1 biomaterial immobilization
Immobilized Jagged1 for bone tissue engineering
Authors

Year

Journal

Cell Type

Application

HES1

HEY1

ALP

2013

Stem Cells

MSCs

osteogenic
differentiation

↑

↑

↑

2013

Journal
Biomedical
Material
Research Part
A

bone marrow
(BM) MSCs

fracture repair

↑

↑

Sukarwan et al

2016

Archives of
Oral Biology

Stem cells in
human
exfoliated
deciduous teeth

osteogenic
differentiation

↑

↑

↑

↑

Manokawinchoke
et al.

2017

Scientific
Reports

dental pulp
MSCs

odonto
differentiation

↑

↑

↑

↑

Ndong et al.

2018

Journal
Biomedical
Material
Research Part
A

fibroblast-like
cells from
embryonic
palatal shelves

osteogenic
differentiation

↑

↑

↑

↑

Nowwarote et al

2018

Archives of
Oral Biology

periodontal
ligament cells

osteogenic
differentiation

↑

↑

↑

Osathanon et al

2019

Archives of
Oral Biology

alveolar and
iliac BM-MSCs

promote bone
mineralization

↑

↑

↑

Zhu et al

Dishowitz et al.

COL1

BSP

OSX

↑

↑

TWIST2

Other

Ref.
10

11

↑

↓

(NS) OPN,
(NS) OCN

12

↓

↑ BMP2,
↑RUNX2

13

↑ RUNX2

14

↑

15

↑

16

↓
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Immobilized Jagged1 for other applications
Source

Year

Journal

Tissue

Cell Type

Application

Notch Markers

Markers

Beckstead et al,
2006

2006

Journal of
Biomedical
Materials Research

Epithelial

Rat esophageal
epithelial cells

Epithelial
differentiation and
stratification

↑ CBFJ-luciferase

↑Caspase3,
↑Occludin
↑involucrin, ↑

17

Gancalves et al,
2009

2009

Biomaterials

Blood

HL-60 leukemia
cell line

blood cell expansion

↑HES1

N/A

18

Osathanon et al,
2013

2013

Stem Cells and
Development

Neurogenic

periodontal
ligament derived
MSCs

Neurogenic
commitment

↑HES1, ↑HEY1

Cardiac and
ectodermal
differentiation

↑ HES1

↑SOX2

Ref.

19

↑B3-tubulin
↑SOX1
↑cardiac troponin
T
↓SM-Actin
↑nkx2-5,
↑MEF2C,
↑GATA4

Tung et al, 2014

2014

Stem Cell Reports

Cardiac

embryonic Stem
cells

Boopathy et al,
2014

2014

Biomaterials

Cardiac

cardiac
progenitor cells

differentiation into
cardiac lineage

↑HEY 1

Wen et al, 2014

2014

Applied Materials
and Interfaces

Cardiac

BM-MSCs

myocardial lineage
commitment

↑HES1, ↑Notch1

↑cTnt(Troponin)
↑Nkx2.5
↑MYH7,↑GATA4

22

Ji et al, 2016

2016

Cellular Physiology
and Biochemistry

Pericytes

Hemangioma
pericytes

Pericyte Phenotype

↑HES1, ↑HEYL, ↑Notch3

↑SM-MHC, ↑SM
actin, ↑myocardin

23

N/A

↑IL-10. ↑TGFbeta, ↓IFNgamma, ↓TNFalpha

24

↑HES1, ↑IRF6, ↑Notch3

↑TGM1, ↑IVL

25

Izadi et al, 2018

2018

Biomaterials

Immunoprotection

pancreatic islets

improved
immunoprotection of
islets

Negri et al, 2019

2019

Scientific Reports

Epidermal

epidermal
keratinocytes

Epidermal
homeostasis
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Appendix A4: Magnetic tweezer design schematic

This is a design schematic for translating the magnetic tweezer apparatus used to determine
molecular mechanotransduction into an automated, microscope-integrated system. This system
would allow for precise control of force application at a greater range than the permeant
magnetic plate used in this thesis and a flow system to minimize contamination and achieve
proper nutrient and oxygen delivery to cell cultures. Integrated into the system is also a camera
for imaging cellular response and bead behavior in real-time. Although the Jagged1-Notch3
system shows a decreased expression of contractile marker expression upon force application,
this system could be used for force application in other cell systems.
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